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ABSTRACT
Short peptides containing Cα,α-dipropylglycine (Dpg) at alternating sequence
positions were synthesized and examined for conformational behavior. Peptide assembly
was performed using Fmoc-solid-phase chemistry where the coupling with PyAOP
could be significantly enhanced at elevated temperature. Circular dichroism (CD) and
NMR conformational studies revealed that incorporation of Dpg residues induced folded
structures into peptides. It was observed that Dpg residues adopted helical conformation
in a helix-promoting sequence. The resulting helical structure was comprised of
consecutive β-turns whose structure was stabilized by salt bridge in aqueous solution.
In this study, the preparation of sterically and polyfunctional Cα,α-disubstituted
amino acids (ααAAs) via alkylation of ethyl nitroacetate and transformation into
derivatives ready for incorporation into peptides are described. Treatment of ethyl
nitroacetate with N,N-diisopropylethylamine in the presence of a catalytic amount of
tetraalkylammonium salt, followed by the addition of an activated alkyl halide or
Michael acceptor, gave the doubly C-alkylated product in good to excellent yields.
Selective nitro reduction with Zn in acetic or hydrogen over Raney Ni gave the
corresponding amino ester that, upon saponification, can be protected with the
fluorenylmethyloxycarbonyl (Fmoc) group. The synthesis of a sterically demanding
Cα,α-dibenzylglycine (Dbzg), and an orthogonally protected, tetrafunctional Cα,αdisubstituted analogue of aspartic acid Bcmg is described.
The preparation of amyloid fibril blocker peptides based on amyloid peptide
hydrophobic core Aβ16-20 is described. These blocker peptides containing sterically

xiii

hindered ααAA are β-strand mimics and are likely to interact with the amyloid
hydrophobic core based on “like likes like” residue relationships. Amino acid
symmetrical anhydride method was employed for the peptide synthesis. It was observed
that Fmoc amino acid symmetrical anhydrides were efficient and readily available
reagents for acylation of the N-terminus of highly hindered ααAAs. Comparison of a
variety of coupling protocols showed that the symmetrical anhydride method always
provided the superior results. Amyloid fibril inhibitor AMY-1 was synthesized and
examined for its biological activities. It was observed that AMY-1 could significantly
reduce the aggregation of amyloidogenic Aβ10-35 at different ratio at either room
temperature and 37 ºC.

xiv

CHAPTER 1
INTRODUCTION
1.1

A Brief Overview of Proteins and Peptides
Proteins, one of the most abundant classes of biomolecules in cells, are present in

virtually all life forms. The term “protein” is derived from the Greek word “proteis”,
which means “first rank of importance”. In biological systems, proteins play a key role
in a variety of chemical and physical processes. They function as enzymes which
catalyze biological reactions in organisms; they act to transport and store biologically
important substances such as oxygen, metal ions, and lipids. In the form of muscle fibers
and other contractile organisms, proteins create and regulate mechanical motion of
numerous biological activities. The many functions of proteins can be understood only in
terms of protein structure. Proteins are linear polymers of amino acids, which are linked
by amide bonds, also called peptide bonds (Figure 1.1). The low molecular weight
polymer of amino acids is termed peptide. The chemical nature and sequential order of
amino acids, and length of a peptide chain determine the characteristic structure of a
protein and a peptide, upon which its biological functions are based.
There are twenty standard amino acids which are commonly found in protein and
peptide sequences. A number of natural peptides have been shown to contain modified

peptide bond
H3+N

O
O
H
H
C C NH C C OR'
R

Figure 1.1 Peptide bond between amino acids.
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forms of some amino acids, such as α-aminoisobutyric acid (Aib, Figure 1.2),1.1-1.4 a
prototype of Cα,α-disubstituted amino acids (ααAAs). Due to their structural features,
incorporation of ααAAs into peptides imposes considerable constraints on the peptide
backbone, and thus may induce specific conformations.1.5-1.8 This chapter will present an
overview of peptide secondary structure and modification of peptide secondary structure
with non-coded ααAAs as well as a summary of methods of assembly of peptide
primary structure.

H3C CH3
N
H

C
O

Figure 1.2 Structure of α-aminoisobutyric acid.

1.2

Peptide Primary and Secondary Structure
Peptides are unbranched polymers of amino acids. The order in which amino

acids are found in a peptide chain is called the peptide primary structure. The primary
structure distinguishes a peptide from other peptides and fundamentally affects all the
chemical and biological properties of the peptide. With 20 common amino acids
available at each residue position, it is easy to form a huge number of peptides with
different sequences. The peptide linkage is the peptide bond (Figure 1.1), formed
between a carboxyl group of one residue and an amino group of another residue. The
peptide C-N bond has partial double bond character due to resonance, which restricts
free rotation around the peptide bond (Figure 1.3, ωi = 0 or 180).1.9 Peptide backbone
2

structure can be described in terms of the dihedral angles between adjacent planar
peptide groups (Figure 1.3).1.9 Rotation about the Cα-N bond is denoted by dihedral
angle φ, where rotation about the Cα-C is denoted by dihedral angle ψ. Rotation of φ and
ψ are restricted due to steric interference between non-bonded atoms. In any case, the
entire peptide backbone conformation is defined if all φ and ψ angles are specified.

Cαi+1
Ni+1

Hi

φi
ωi

Cαi-1

Hi+1

Ci

Oi

ψi
Ciα

Ni

Ci-1
Oi-1

Figure 1.3 Dihedral angles of the peptide backbone.

There are several different types of noncovalent forces involved in stabilizing peptide
conformations. The primary force is hydrogen bonds. Others include hydrophobic
interactions, electrostatic bonds and van der Waals forces. Through hydrogen bonding
between amino acid residues, the peptide chain can arrange itself into distinctive patterns,
and such a characteristic structure is called peptide secondary structure. Peptide secondary
3

Table 1.1 Typical dihedral angles for common peptide secondary structures.
Conformation

a

Dihedral angle (degree)
φ
ψ

Residues per turn

Right-handed α-helix

-57

-47

3.6

Right-handed 310-helix

-49

-26

3.0

Anti-parallel β-sheet

-139

+135

2.0

Parallel β-sheet

-119

+113

2.0

Type I β-turna

-60 (-90)

-30 (0)

3.0

Type II β-turna

-60 (+90)

+120 (0)

3.0

For β-turns, the dihedral angles from two consecutive amino acids in the middle of the
turn are used to define the structure. The 1st angle is for the i + 1 residue and the second
number in parenthesis is the i + 2 residue of the turn.

structure can be divided into three general categories, helix, β-sheet, and β-turn, where
each conformation has its characteristic dihedral angles (Table 1.1).1.10
The right-handed α-helix is the most prevalent helical structure and accounts for
approximately 31% of the residues in known globular proteins.1.10 The α-helical
structure is stabilized by intramolecular hydrogen bonding between the carbonyl oxygen
of each residue and the NH of the fourth residue along the chain (Figure 1.4). These
hydrogen bonds have a length of about 2.86 Å from the oxygen to the nitrogen and are
nearly parallel to the helix axis. Right-handed α-helices range in size from 4 to 40
residues. There are 3.6 residues per turn and each residue extends 1.5 Å along the helix
axis. Multiple forms of helices are found in natural occurring proteins and peptides and
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-

-
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N H

O
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O

O
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O
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O

O

N H

N H
O

O
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H N

O

O

N H

N H
O

O

H N

H N
O

O

N H

N H
O

O

H3+N

H3+N

α-Helix

310-Helix

Figure 1.4 Hydrogen bonding patterns in α-helix and 310-helix.
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one of the common forms is 310-helix. The 310-helix accounts for about 10% of all
helical structures in proteins and it is usually located at the ends of α-helices.1.11-1.12
In 310- helices there are 3 residues per turn and 10 atoms per ring formed between the
hydrogen-bonded amide proton and carbonyl oxygen (Figure 1.4). The packing of the
backbone atoms in 310-helices is very tight and they typically have less residues on
average than α-helices.
After the α-helix, the second most abundant structural element in proteins is the
β-sheet. There are approximately 28% of the residues in recognized globular proteins are
found in β-sheets.1.10, 1.13 The β-sheet conformation depends on intermolecular hydrogen
bonding between the nearly fully extended peptide chains, called β-strands. In all
recognized β-sheets, the β-strands have a twisted conformation and can be considered as
a special helix with 2.0 residues per turn and a translation of 3.4 Å per residue. The βstrand conformation is stable only when incorporated into β-sheet where it forms
hydrogen bonds with peptide groups on neighboring strands (Figure 1.5).
The β-sheet can exist in two varieties: parallel and antiparallel β-sheet. In a
parallel structure the neighboring peptide chains are aligned in the same N-to-C terminus
direction, while in an antiparallel structure the neighboring peptide chains are aligned in
an opposite direction as shown in Figure 1.5. β-sheets can consist of pure parallel or
antiparallel strands or can have a mixture of the two strands.1.10 β-sheets are important
structural elements in both fibrous and globular proteins. Many proteins, including
carbonic anhydrase and glyceraldehyde phosphate dehydrogenase, contain both αhelices and β-pleated sheet structures in a single polypeptide chain.1.14

6
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Figure 1.5 Hydrogen bonding patterns in β-sheets.

The third common form of peptide secondary structure is called β-turn. β-Turn is
an important component of protein structures and it comprises nearly 25% of the
residues of globular proteins.1.10, 1.15 A β-turn involves four consecutive residues and it
reverses or folds back the peptide chain by nearly 180 degrees. β-Turns are often
stabilized by a hydrogen bond between the carbonyl oxygen of residue i and amide
proton of residue i + 3 (Figure 1.6). There are two common types of β-turn, type
I and type II β-turn. Additionally, there are two variants, type I’ and type II’ β-turn, which
7

H
N
O

O
NH

H
N
O

Figure 1.6 Hydrogen bonding pattern in a β-turn.

are mirror images of the backbone of type I and type II β-turn, respectively. In protein
structure, type I and II β-turns occur more frequently than variants type I’ and II’, though
the type I’ is generally located in β-hairpins.1.10, 1.15
1.3

Cα,α-Disubstituted Amino Acids and the Promoted Peptide Secondary
Structure

1.3.1

α-Aminoisobutyric Acid
Cα,α-disubstituted amino acids (ααAA) are a class of non-coded amino acids in

which the presence of two substitutents (usually alkyl groups) at the α-carbon imposes
intense constraints on the φ/ψ angles of the residue (Figure 1.7). The most commonly
studied ααAA is certainly α-aminoisobutyric acid (Aib). Aib is a naturally occurring
amino acid produced by microbial sources,1.1-1.4 typically by non-ribosomal peptide
synthesis. It is known that Aib residues have dramatic influences on peptide backbone
conformation.1.16-1.20 In an Aib residue, the rotation about N-Cα and Cα-C’ bond is
restricted. The energy minimum for the dihedral angle φ and ψ of Aib occur near –57º,
-47º and 57º, 47º respectively, which corresponds to a right-handed or left-handed αhelix or 310-helix in Ramachandran plot.1.18, 1.21-1.22 Early studies on alamethicin crystal
8

R R
H2N

CO2H

Aib R = methyl

Deg R = ethyl

Dpg R = propyl

Dbzg R = benzyl

Figure 1.7 Representative Cα,α-disubstituted amino acids.
structure by Fox and Richards showed this Aib-containing peptide adopted a mixture of
310- and α-helical structures in the solid state.1.23 Since the 1980s, a number of groups
such as Balaram’s and Toniolo’s group, have done extensive studies on Aib peptide
conformation.1.16, 1.18-1.19 Studies have shown that Aib peptides can adopt α, 310 or α/310helical structures depending on sequence length, Aib content, and solvent effects.1.7, 1.18,
1.24

It has been reported that the minimal length for a peptide to form an α-helix is seven

residues, while no significant chain length is required for 310-helix formation. Peptides
with more than 8 residues are more likely to adopt an α-helix than a 310-helix, if the Aib
residue content is not more than 50%. Meanwhile, even a single α-helix chain often has
310-helices present at either end of the stretch which tightens up the ends of the α-helix
structure.1.10 It has been found that solvents also effect the conformational preference of
Aib rich peptides.1.5, 1.7, 1.25 In peptides where the α/310-helix equilibrium exists, solvents
with high polarity usually favor the α-helix formation, while the 310-helix is often found
in low polarity solvent systems.

9

1.3.2

Cα,α-Disubstituted Amino Acids with Large Side Chains
In peptides containing Cα,α-disubstituted amino acid residues, the range of

accessible backbone conformation is greatly restricted. Conformational energy
calculation of the higher alkyl analogs of Aib, such as Cα,α-diethylglycine (Deg) and
Cα,α-dipropylglycine (Dpg), shows that the fully extended conformation (φ ∼ ψ ∼ 180º) is
more energetically favorable than 310/α-helical conformation (Table 1.2).1.26-1.27

Table 1.2 Minimum energy conformations for Deg and Dpg derivatives.
Compound

a

Dihedral angle (degree)
φ
ψ

∆Ea
Kcal/mol

Structure

Ac-Deg-NHMe

-179.5
55.5

-179.4
45.9

0.0
1.8

Extended
Helix

Ac-Dpg-NHMe

-179.3
-57.5

-178.6
-52.6

0.0
3.59

Extended
Helix

Conformational energies are expressed ∆E = E – E0, where E0 is the energy of the most
stable conformation.
Early structural studies of short homopeptides containing Deg or Dpg showed the

extended conformation in peptide crystal structure, was consistent with theoretical
findings.1.26-1.29 In the structural analysis of a biologically active peptide analog, Nformyl-Met-Dpg-Phe-OMe, Dentino et al also observed an extended backbone
conformation at the Dpg residue.1.30 However, there is growing body of evidence
showing that Dpg residues can adopt helical conformation, especially in heteromeric
peptides.1.31-1.33 For example, in the peptide Boc-Gly-Dpg-Leu-Val-Ala-Leu-Aib-ValAla-Leu-OMe, the dihedral angles φ and ψ at the Dpg residue are -51º and -47º
10

respectively, corresponding to an α-helical conformation.1.34 Interesting, in the single
crystal of peptide Boc-Leu-Dpg-Val-OMe, both helical and extended conformation were
found at Dpg residue.1.35 In fact, the energy difference between an extended and helical
structure at a Dpg residue is context dependent and affected by sequence composition
and length, and other residues’ preference for helical or extended structure.
1.4

Solid-Phase Peptide Synthesis
Solid-phase peptide synthesis (SPPS) involves anchoring a peptide chain to an

insoluble polymeric support and extending the peptide chain by stepwise addition of a
series of amino acid residues. Introduced by Merrifield in 1950s,1.36 the SPPS method
has evolved over the past five decades and has become the primary route for peptide
preparation. In solid-phase peptide synthesis, the anchored peptide chain is assembled by

O
H2N

Y
R1

Prot

O

H
N

X
R2

R2
Prot

N
H

O

H
N
O

Y

Y = NH, O

R1

Figure 1.8 Amide bond formation in SPPS.
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stepwise addition of Nα-protected amino acid residues in the C → N direction (Figure
1.8). There are several major types of coupling reagents utilized for the carboxy
activation process. The most commonly used reagent is 1,3-dicyclohexylcarbodiimide
(DCC, see Figure 1.9). In the presence of a carbodiimide reagent, an Nα-protected amino
acid forms an activated O-acylisourea which undergoes aminolysis to form a peptide
linkage and dicyclohexylurea (DCU). A water-soluble carbodiimide, 1-ethyl-3-(3’dimethylaminopropyl)carbodiimide hydrochloride (EDCI), is also a commonly used
coupling agent. The EDCI produces a soluble urea derivative which can be easily
removed by an aqueous wash step.1.37 Carbodiimide-mediated couplings can be
enhanced by the presence of a coupling additive, such as 1-hydroxybenzotriazole
(HOBt) and 1-hydroxy-7-azabenzotriazole (HOAt).1.38-1.39 Such additives reduce side
reactions and racemization of the activated amino acid involved couplings.

Me
Me N

N C N

N C N Et

EDCI

DCC

N

N
N
N
OH

N

HOBt

N
N
OH

HOAt

Figure 1.9 Carbodiimide reagents and coupling additives.
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During the last twenty years, a number of uronium and phosphonium salts based
upon HOBt and HOAt have been developed. Examples in these categories include O-(7azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU),1.39 O(7-azabenzotriazol-1-yl)-tris(dimethylamino)phosphonium hexafluophosphate (AOP),1.40
1-benzotriazolyoxytris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP),1.41 and
7-azobenzotriazolyoxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP).1.42
Normally, these reagents are used in the presence of an equimolar amount of the acid,
with a tertiary amine in solvents such as DMF and acetonitrile. In general, these reagents
are found to be highly efficient in peptide couplings typically without any appreciable
racemization or side-product formation.
OH
N
N
PF6
N

N
Me2N

N
N
N

NMe2

PF6

P(NMe2)3

AOP

HATU

N

N
N
N
O

N
O

N

PF6

P N

N
3

N
O

PF6

P N

3

PyAOP

PyBOP

Figure 1.10 Uronium and phosphonium salts based on HOBt and HOAt.
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Mixed anhydride activation protocols are another common alternative for peptide
bond formation. This method involves aminolysis of an anhydride formed between a Nαprotected

amino

acid

and

oxazolidinyl)phosphinic

another

chloride

acid

(BOP-Cl)

moiety,
and

such

as

bis(2-oxo-3-

2-ethoxy-1-ethoxycarbonyl-1,2-

dihydroquinoline (EEDQ).1.43-1.44 Additional coupling protocols or reagents that have
been applied for peptide assembly include the amino acid halides and azides.1.45 In these
methods, the activated acids can be prepared and purified prior to coupling or formed
more conveniently in situ by reagents like cyanuric fluoride to give acid fluorides.
Diphenyl phosphorylazide (DPPA) can also directly convert a free carboxyl group to an
azide intermediate.1.46

O

N

O

O
O
N
P
O
Cl

N
O

R
N
H

OEt

EEDQ

BOP-Cl

Prot

OEt

O
O
P
O N3

X
O

X = F, Cl

Acid halide

DPPA

Figure 1.11 Alternate coupling reagents for peptide assembly.
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1.5

Peptide Structure Analysis
Peptide structure analysis is the characterization of peptide three-dimensional

structures by which peptide biological properties or mode of activities can be deduced.
There are several experimental techniques such as X-ray crystallography, solution
nuclear magnetic resonance (NMR) spectroscopy, circular dichroism (CD) spectroscopy,
and Fourier transform infrared spectroscopy (FTIR) that have been developed for
structural analysis of peptides.
The X-ray crystallography was widely used to detected peptide threedimensional structure in the early years. The X-ray detected structure could provide
detailed information such as bond length and bond angle in a quantitative way. Multiple
X-ray analyses of a peptide can elucidate a finite number of conformational classes
accessible to a peptide.1.47 However, difficulties in crystalline sample preparation and the
conformational difference between peptides in the solid state and its form in biological
environments limit the wide application of X-ray crystallography to peptide structure
evaluation.
Solution NMR spectroscopy is a powerful tool for protein and peptide structure
sanalysis. The NMR studies use noncrystalline samples and the solution conditions can
be varied over a wide range. The NMR input for peptide conformational study mainly
depends on nuclear Overhause effects (NOE) and coupling constants. A NOE detects
interproton distances of 5Å or less, while the coupling constants reflects torsion angles.
The measured NOEs and coupling constants are collected and converted to proton
distances and torsion angles, which are indicative of certain peptide secondary structure.
Typically, the whole set of NOE constraints are utilized in certain computational
15

programs to search for the entire conformation space, from which the optimized solution
structures of the peptides are obtained.
Circular dichroism (CD) spectroscopy is a commonly used method for
identifying peptide conformation in solution. In general, the bands in the far-UV region
(180-250 nm) of a CD spectrum are indicative of peptide secondary structures, while the
bands in the near-UV region (250-350 nm) often reflect the contribution of certain
functional groups, such as aromatic side chains and disulfide bonds.1.48-1.49 The typical

Curve
1 100% α-helix
2 100% β-sheet
3 100% random coil

Figure 1.12 CD spectra of typical peptide secondary structures.
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CD spectra for major types of peptide secondary are illustrated in Figure 1.12.1.50 An αhelix exhibits two negative CD bands around 207 nm (π→π*) and 222 nm (n→π*) and a
positive band around 192 nm (π→π*). The β-sheet has two characteristic minima at 197
nm and 216 nm respectively, however, even a single negative band at 216 nm is often a
good indication of β-sheet content. The CD spectra of random coils usually display a
large negative band near 196 nm.
Fourier transform infrared spectroscopy (FTIR) is an alternate technique for
peptide conformational studies. The major input of FTIR is the measurement of N-H
band and the amide I band which are correlated with secondary structures.1.51 The FTIR
data measurement is complementary to that of NMR and CD, and it has been used to
examine peptides that tend to aggregate.1.52-1.53
1.6

References

1.1

Bachet, B.; Brassy, C.; Morize, I.; Surcouf, E.; Mornon, J. P.; Bodo, B.;
Rebuffat, S. Crystallization and preliminary x-ray diffraction results of
trichorzianine A 1, a peptide with nineteen residues from Trichoderma
harzianum. J. Mol. Biol. 1983, 170, 795-796.

1.2

Vijayakumar, E. K. S.; Balaram, P. Solution conformations of penta- and
heptapeptides containing repetitive α-aminoisobutyryl-L-alanyl and αaminoisobutyryl-L-valyl sequences. Tetrahedron 1983, 39, 2725-2731.

1.3

Pandey, R. C.; Cook, J. C.; Rinehart, K. L. Structures of the peptide antibiotics.
Emerimicins III and IV 1,2. J. Am. Chem. Soc. 1977, 99, 5205-5206.

1.4

Jung, G.; Bruckner, H.; Schmitt, H. X-ray structure and spectroscopic properties
of Boc-L-Ala-(Aib-Ala)2-Glu(OBzl)-Ala-(Aib-Ala)2-OMe, a model of the
alamethicin helix. In Structure and Activity of Natural Peptides, Voelter, W. and
Weitzel, G., Eds., de Gruyter, Berlin, 1981, pp. 75-114.

1.5

Formaggio, F.; Crisma, M.; Rossi, P.; Scrimin, P.; Kaptein, B.; Broxterman, Q.
B.; Kamphuis, J.; Toniolo, C. The first water-soluble 310-helical peptides. Chem.Eur. J. 2000, 6, 4498-4504.

17

1.6

Vijayalakshmi, S.; Rao, R. B.; Karle, I. L.; Balaram, P. Comparison of helixstabilizing effects of α,α-dialkyl glycines with linear and cycloalkyl side chains.
Biopolymers 2000, 53, 84-98.

1.7

Yokum, T. S.; Gauthier, T. J.; Hammer, R. P.; McLaughlin, M. L. Solvent effect
on the 310/α-helix equilibrium in short amphipathic peptides rich in α,αdisubstituted amino acids. J. Am. Chem. Soc. 1997, 119, 1167-1168.

1.8

Wysong, C. L.; Yokum, T. S.; McLaughlin, M. L.; Hammer, R. P. Controlling
peptide structure. CHEMTECH 1997, 27, 26-33.

1.9

Branden, C.; Tooze, J. Introduction to Protein Structure; Garland Publishing:
New York, 1991; pp. 180-191.

1.10

Ceighton, T. E. Proteins: Structure and Molecular Properties; 2nd ed; W. H.
Freeman and Co.: New York, 1993; pp. 65-68.

1.11

Toniolo, C.; Benedetti, E. The polypeptide 310 helix. Trend Biochem. Sci. 1991,
16, 350-353.

1.12

Barlow, D. J.; Thornton, J. M. Helix geometry in proteins. J. Mol. Biol. 1988,
201, 601-619.

1.13

Walton, A. G. Polypeptides and Protein Structure; Elsevier: New York, 1981;
pp. 49-55.

1.14

Garrett, R. H.; Grisham, C. M. Biochemistry; Saunders College Publishing: Fort
Worth, 1995; pp. 58-62.

1.15

Chou, K-C.; Blinn, J. R. Classification and prediction of beta-turn types. J.
Protein Chem. 1997, 16, 575-595.

1.16

Prasad, B .V.; Balaram, P. The stereochemistry of peptides containing alphaaminoisobutyric acid. CRC Crit. Rev. Biochem. 1984, 16, 307-348.

1.17

Augspurger, J. D.; Bindra. V. A.; Scheraga, H. A.; Kuki, A. Helical stability of
de novo designed α-aminoisobutyric acid-rich peptides at high temperatures.
Biochemistry 1995, 34, 2566-2576.

1.18

Karle, I. L.; Balaram, P. Structural characteristics of alpha-helical peptide
molecules containing Aib residues. Biochemistry 1990, 29, 6747-6756.

1.19

Di Blasio, B.; Pavone, V.; Saviano, M.; Lombardi, A.; Nastri, F.; Pedone, C.;
Benedetti, E.; Crisma, M.; Anzolin, M.; Toniolio, C. Structural characterization
of the β-bend ribbon spiral: crystallographic analysis of two long (L-Pro-Aib)n
sequential peptides. J. Am. Chem. Soc. 1992, 114, 6273-6278.
18

1.20

Marshall, G. R.; Hodgkin, E. E.; Lansi, D. A.; Smith, G. D.; Zabrocki, J.;
Leplawy, M. T. Factors governing helical preference of peptides containing
multiple alpha,alpha-dialkyl amino acids. Proc. Natl. Acad. Sci. U.S.A 1990, 87,
487-491.

1.21

Marshall, G. R.; Bosshard, H. E. Angiotensin II. Studies on the biologically
active conformation. Circ. Res. 1972, 30/31(suppl. II), 143-150.

1.22

Benedetti, E. X-ray crystallography of peptides: the contributions of the Italian
laboratories. Biopolymers 1996, 40, 3-44.

1.23

Fox, R. O., Jr.; Richards, F. M. A voltage-gated ion channel model inferred from
the crystal structure of alamethicin at 1.5-ANG. resolution. Nature (London)
1982, 300, 325-330.

1.24

Toniolo, C.; Benedetti, E. Structures of polypeptides from α-amino acids
disubstituted at the α-carbon. Macromolecules 1991, 24, 4004-4009.

1.25

Kenedy, D. F.; Crisma, M.; Toniolo, C.; Chapman, B. Studies of peptides
forming 310- and α-helixes and β-bend ribbon structures in organic solution and
in model biomembranes by Fourier transform infrared spectroscopy.
Biochemistry 1991, 30, 6541-6548.

1.26

Benedetti, E.; Barone, V.; Bavoso, A.; Di Blasio, B.; Lelj, F.; Pavone, V. Pedone,
C.; Bonora, G. M.; Toniolo, C.; Leplawy, M. T.; Kaczmarek, K.; Redlinske, A.
Structural versatility of peptides from Cα,α-dialkylated glycines. I. A
conformational energy computation and x-ray diffraction study of homopeptides
from Cα,α-diethylgylcine. Biopolymers 1988, 27, 357-371.

1.27

Benedetti, E.; Toniolo, C.; Hardy, P.; Barone, V.; Bavoso, A.; Di Blasio, B.;
Grimaldi, P.; Lelj, F.; Pavone, V.; Pedone, C.; Bonora, G. M.; Lingham, I.
Folded and extended structures of homooligopeptides from α,α-dialkylated
glycines. A conformational energy computation and x-ray diffraction study. J.
Am. Chem. Soc. 1984, 106, 8146-8152.

1.28

Bonora, G. M.; Toniolo, C.; Di Blasio, B.; Pavone, V.; Pedone, C.; Benedetti, E.;
Lingham, I.; Hardy, P. Folded and extended structures of homooligopeptides
from α,α-dialkylated α-amino acids. An infrared absorption and proton nuclear
magnetic resonance study. J. Am. Chem. Soc. 1984, 106, 8152-8156.

1.29

Toniolo, C.; Bonora, G. M.; Bavoso, A.; Benedetti, E.; Di Blasio, E.; Pavone, V.;
Pedone, C.; Barone, V.; Leji, F.; Leplawy, M. T.; Kaczmarek, K.; Redlinski, A.
Structural versatility of peptides from Cα,α-dialkylated glycines. II. An IR
absorption and proton NMR study of homooligopeptides from Cα,αdiethylglycine. Biopolymers 1988, 27, 373-379.

19

1.30

Dentino, A. R.; Raj, P. A.; Bhandary, K. K.; Wilson, M. E.; Levine, M. J. Role of
peptide backbone conformation on biological activity of chemotactic peptides. J.
Biol. Chem. 1991, 266, 18460-18468.

1.31

Karle, I. L.; Rao, R. B.; Prasad, S.; Kaul, R.; Balaram, P. Nonstandard Amino
Acids in Conformational Design of Peptides. Helical Structures in Crystals of 510 Residue Peptides Containing Dipropylglycine and Dibutylglycine. J. Am.
Chem. Soc. 1994, 116, 10355-10361.

1.32

Karle, I. L.; Rao, R. B.; Kaul. R.; Prasad, S.; Kaul, R.; Balaram, P Peptide
design: crystal structure of a helical peptide module attached to a potentially
nonhelical amino terminal. Biopolymers 1996, 39, 75-84.

1.33

Datta, S.; Kaul, R.; Rao, R. B.; Shamala, N.; Balaram, P. Stereochemistry of
linking segments in the design of helix-helix motifs in peptides. Crystallographic
comparison of a glycyl-dipropylglycyl-glycyl segment in a tripeptide and a 14residue peptide. J. Chem. Soc. Pekin. Trans. 1997, 2, 1659-1664.

1.34

Kaul, R.; Banumathi, S.; Velmurugan, D.; Rao, R. B.; Balaram, P.
Conformational choice at α,α-di-n-propylglycine residues: helical or fully
extended structures? Biopolymers 2000, 54, 159-167.

1.35

Prasad, S.; Mitra, S.; Subramanian, E.; Velmurugan, D.; Rao, R. B.; Balaram, P.
Coexistence of folded and extended conformations of a tripeptide containing
alpha, alpha -di-n-propylglycine in crystals. Biochem. Biophys. Res. Commun.
1994, 198, 424-430.

1.36

Merrifield, R. B.; Woolley, D. W. The synthesis of L-seryl-L-histidyl-L-leucylL-valyl-L-glutamic acid, a peptide with streptogenin activity. J. Am. Chem. Soc.
1956, 78, 4646-4649.

1.37

Sheehan, J. C.; Cruickshank, P. A.; Boshart, G. L. Convenient synthesis of watersoluble carbodiimides. J. Org. Chem. 1961, 26, 2525-2528.

1.38

Konig, W.; Geiger, R. A. new method for the synthesis of peptides: activation of
the carboxy group with dicyclohexylcarbodiimide and 3-hydroxy-4-oxo-3,4dihydro-1,2,3-benzotriazine. Chem. Ber. 1970, 103, 2034-2040.

1.39

Carpino, L. A. 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling
additive. J. Am. Chem. Soc. 1993, 115, 4397-4398.

1.40

Carpino, L. A.; El-Faham, A; Albericio, F. Racemization studies during solidphase peptide synthesis using azabenzotriazole-based coupling reagents.
Tetrahedron 1994, 35, 2279-2280.

1.41

Coste, J.; Le-Nguyen, D.; Castro, B. PyBOP: a new peptide coupling reagent
devoid of toxic byproduct. Tetrahedron 1990, 31, 205-208.
20

1.42

Albericio, F.; Cases, M.; Alsina, J.; Triolo, S. A.; Carpino, L. A.; Kates, S. A. On
the use of PyAOP, a phosphonium salt derived from HOAt, in solid-phase
peptide synthesis. Tetrahedron Lett. 1997, 38, 4853-4856.

1.43

Diago-Meseguer, J.; Palomo-Coll, A. L.; Fernandez-Lizarbe, J. R.; ZugazaBilbao, A. A new reagent for activating carboxyl groups: preparation and
reactions of N, N-bis[2-oxo-3-oxazolidinyl]phosphorodiamidic chloride.
Synthesis 1980, 547-552.

1.44

Belleau, B.; Malek, G. A new convenient reagent for peptide syntheses. J. Am.
Chem. Soc. 1968, 90, 1651-1652.

1.45

Carpino, L. A.; Beyermann, M.; Wenschuh, H.; Bienert, M. Peptide Synthesis
via Amino Acid Halides. Accounts Chem. Res. 1996, 29, 268-274.

1.46

Ninomiya, K; Shioiri, T; Yamada, S. Amino acids and peptides. XII. Phosphorus
in organic synthesis. VIII. Reaction of malonic acid half esters with diphenyl
phosphorazidate. Chem. Pharm. Bull. 1974, 22, 1398-1404.

1.47

Rao, S. N. Bioactive conformation of Arg-Gly-Asp by x-ray data analyses and
molecular mechanics. Pept. Res. 1992, 5, 148-155.

1.48

Woody, R. W. The circular dichroism of aromatic polypeptides: theoretical
studies of poly-L-phenylalanine and some para-substituted derivatives.
Biopolymers 1972, 11, 1149-1171.

1.49

Manning, M. C.; Woody, R. W. Theoretical study of the contribution of aromatic
side chains to the circular dichroism of basic bovine pancreatic trypsin inhibitor.
Biochemistry 1989, 28, 8609-8613.

1.50

Greenfield, N.; Fasman, G. D. Computed circular dichroism spectra for the
evaluation of protein conformation. Biochemistry 1969, 8, 4108-4116.

1.51

Wi, S.; Pancoska, P.; Keiderling, T. A. Predictions of protein secondary
structures using factor analysis on Fourier transform infrared spectra: effect of
Fourier self-deconvolution of the amide I and amide II bands. Biospectroscopy
1998, 4, 93-106.

1.52

Gasset, M.; Baldwin, M. A.; Lloyd, D. H.; Gabriel, J. M.; Holtzman, D. M.;
Choen, F.; Fletterick, R.; Prusiner, S. B. Predicted alpha-helical regions of the
prion protein when synthesized as peptides form amyloid. Proc. Natl. Acad. Sci.
U.S.A. 1992, 89, 10940-10944.

1.53

Lansbury, P. T., Jr. In pursuit of the molecular structure of amyloid plaque: new
technology provides unexpected and critical information. Biochemistry 1992, 31,
6865-6870.
21

CHAPTER 2
SOLUTION CONFORMATION OF SHORT SYNTHETIC PEPTIDES
CONTAINING Cα,α-DIPROPYLGLYCINE
2.1

Introduction
The incorporation of non-proteinogenic Cα,α-disubstituted amino acid (ααAA)

residues greatly restricts the range of the peptide accessible backbone conformation and
thus induces distinct secondary structures even in short peptides.2.1-2.7 The most
commonly studied ααAA is certainly α-aminoisobutyric acid (Aib). Extensive studies of
Aib peptides have shown the strong preference of this residue for 310/α-helix
conformation.2.3-2.6,

2.8

Indeed, the most energetically favorable conformations for Aib

residues almost invariably fall in the helical region of φ and ψ space (φ = ±60º,
ψ = ±30º). The torsion angles at ααAA residues by which the local conformation is
defined mainly depend on the size of ααAA side chains. Computional studies showed
that the higher alkyl analogs of Aib, such as C α,α -diethylglycine (Deg) and C α,α -

O

H
N

R

R

Deg R = ethyl
Dpg R = propyl

Figure 2.1 Extended C-5 conformation in ααAAs.
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dipropylglycine (Dpg), have significant energy minima in the fully extended (C-5)
region of φ and ψ space (φ = ±180º, ψ = ±180º).2.9-2.10 In the derivative of Ac-xxx-NHMe
(xxx = Deg, Dpg, Aib), the extended C-5 conformation is energetically favored over
helical conformation in both Deg and Dpg derivatives (Figure 2.1).2.9-2.10 In contrast, the
helical regions of φ and ψ space are pronounced energy minima for Aib residue.
Interestingly, the conformational energy difference between the extended structure and
the helical structure in both Deg and Dpg derivatives is often very small, which makes it
possible for Deg and Dpg to adopt either helical or extended conformations. This
characteristic property of the higher alkyl analogs of Aib has evoked particular interest
in the study of their value as peptide secondary structure promoters. In this chapter we
describe the synthesis and conformational analysis of short peptides with designed
sequences stabilizing the fully extended conformation in the Dpg peptides.
In this work, a number of peptides containing natural α-amino acids and Dpg
residues at alternating sequence positions were designed for conformational studies (Table
2.1). In these peptide sequences, none of the L-amino acids had a strong preference for
adopt helical conformation. Meanwhile the Dpg residues had some preference for
extended region of φ and ψ space. The incorporation of Dpg could significantly affect
backbone constraints in these peptides and thus promote extended conformations. The
purpose of preparation of these Dpg peptides is to examine the potential for β-strand
aggregation through interstrand H-bonding and side-chain side-chain interactions. In
both parallel and anti-parallel β-sheet, the pleating of the sheet is largely due to
avoidance of steric interactions of the α-Hs inside the strand. If the α-Hs outside the
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Table 2.1 Primary sequences of Dpg and Nva peptides.
Peptide

R1

R2

R3

R4

DPG-1

Ac-Lys

Dpg

Tyr

Dpg Lys-NH2

DPG-2

Ac-Glu

Dpg

Tyr

Dpg Lys-NH2

DPG-3

Ac-Glu

Dpg

Tyr

Dpg Glu-NH2

DPG-4

Ac-Lys

Dpg

Val

Dpg

DPG-5

Ac-Glu

Dpg

Thr

Dpg Lys-NH2

NVA-2

Ac-Glu

Nva

Tyr

Nva

Lys-NH2

NVA-5

Ac-Glu

Nva

Thr

Nva

Lys-NH2

a

R5

Thr

R6

R7

R8

R9

Dpg

Val

Dpg

Glu-NH2

Sequences are written from the N-terminus to the C-terminus. In all cases C terminus is
a primary amide (CO–NH2).

strands are replaced with alkyl groups, in other words the natural amino acids at
alternating positions are replaced with ααAAs, then it still allows hydrogen bonding
from the inside edge, while blocking further hydrogen bonding formation from the
opposite edge (Figure 2.2). In this study, the peptides containing Dpg residues were
predicted to adopt extended conformation and interact with another strand to form a
dimer in an anti-parallel β-sheet sheet pattern (Figure 2.3). In our design, the
incorporation of lysine and glutamic acid residues at each ends of peptide DPG-2, DPG4, and DPG-5 was designed to probe the potential conformational effect resulting from
residue-residue side-chain interactions (salt bridge). Peptides DPG-1 and DPG-3 where
both ends of the sequence are either lysine or glutamic acid were designed as a
comparison to DPG-2 to check for salt bridge formation. DPG-5 is an analogue of DPG-2,
where the center residue is replaced by threonine to detect the conformational behavior
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Figure 2.3 Proposed dimer formation with DPG-2.

difference. To further investigate ααAA’s impact on peptide backbone conformation, we
prepared two peptide analogues NVA-2 and NVA-5, where Dpg residues are replaced by
the α-amino acid L-norvaline.
2.2

Results and Discussion

2.2.1

Synthetic Approach to Nα-Protected ααAAs
The synthesis of Να-Fmoc-Cα,α-dipropylglycine (Fmoc-Dpg-OH) and Να-Fmoc-

Cα,α-diisobutylglycine (Fmoc-Dibg-OH) started with formation of the hydantoins with
Bucherer-Bergs procedure.2.11-2.12 A high yield of dipropyl-hydantoin was obtained from
dipropyl ketone at room temperature, while the reaction with diisobutyl ketone needed to
be carried out under reflux, and only a moderate yield was obtained after a prolonged
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KCN, (NH4)2CO3

O
R

R

R
O

MeOH/H2O
r.t.a or refluxb

5N NaOH/Refluxa

R
NH

HN

R
+

or 6N KOHb
1750C, 15psi

O

2.1a 82%
2.1b 45%

H3N

CO22.2a 79%
2.2b 49%

Fmoc-Cl

TMS-Cl
DIEA

R
a R = CH2CH2CH3
b R = CH2CH(CH3)2

R

FmocHN

R
CO2H
2.3a 68%
2.3b 56%

Figure 2.4 Synthesis of Fmoc-Dpg-OH and Fmoc-Dibg-OH.

time. Furthermore, hydrolysis of diisobutyl-hydantoin required harsher conditions than
those for the dipropyl-hydantoin. Even under prolonged heating the hydrolysis of the
sterically demanding diisobutyl-hydantoin was not completed (a significant amount of
the hydantoin was recovered from reaction mixture). The ααAAs were isolated by
lyophilizing the neutralized filtrate and extracting the resulting powder with
ethanol/acetone mixture. A small amount of the amino acid was also recovered from
extracting the precipitate formed during the neutralization process. The free ααAAs
were Nα-protected to allow for solid-phase peptide synthesis. Protection of the amine
with Fmoc-Cl using an in situ silylation procedure2.13 provided Fmoc-Dpg-OH and
Fmoc-Dibg-OH in good yields.
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2.2.2

Synthesis of Peptides Containing Dpg and Nva
All peptides were prepared by solid-phase peptide synthesis using the Fmoc

strategy.2.14 The natural amino acids, lysine, tyrosine, threonine, and glutamic acid were
orthogonally protected and the side-chain protection were removed during cleavage. The
Dpg component was introduced to the peptide via Nα-protected derivative, Fmoc-DpgOH. The Fmoc-protected Dpg derivative has high solubility in DMF and can be readily
employed in the automated synthesis system. Peptide bond formation with ααAAs is
inherently problematic due to the steric hindrance at the tetrasubstituted α-carbon.
Traditional activation methods, such as carbodiimide protocol, are usually inefficient for
ααAA coupling, suffering from low yields, slow reaction rates, and a necessity for large
excess of reagents.2.15 In the last two decades, a number of improved coupling reagents
have been developed for efficient peptide assembly. Carpino et al. reported synthesis of
peptides of difficult sequences with a phosphonium salt based on HOAt, called 7azobenzotriazolyoxytris(pyrrolidino)phosphonium hexafluorophosphate (PyAOP, see
Chapter 1 for the structure).2.16 PyAOP has been successfully applied for the preparation
of a range of peptides containing hindered amino acids, such as Aib. We therefore
attempted the synthesis of Dpg peptides using PyAOP protocol. All peptides in this work
were assembled on Perseptive Biosystem Peptide Synthesizer 9050 with Fmoc-PALPEG-PS resin as the solid support. The coupling was performed in N, Ndimethylformamide (DMF) using 4 equiv. of PyAOP, 8 equiv. of diisopropylethyl
amine (DIEA), and 4 equiv. of amino acids (0.3 M). It was found that coupling onto Ntermini of ααAAs could be greatly improved at elevated temperatures (Table 2.2). When
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the synthesis of peptide DPG-1 with PyAOP protocol was carried out at room
temperature, coupling at the C-terminus was straightforward. In contrast, the acylation of
N-terminus of Dpg at room temperature turned out to be difficult (Table 2.2, entries 1,
3). When the acylation was performed at 50 ºC, much improved yields were obtained
(Table 2.2, entries 2, 4). These results were in line with the report that coupling at N-

Table 2.2 Coupling of amino acids onto N-terminus of resin bound Dpg residue.
Entry

a

Coupling amino acid

Activation method

1

Fmoc-Tyr(OtBu)-OH

PyAOP/DIEA/DMF

2

Fmoc-Tyr(OtBu)-OH

3
4

Time
(h)

Temp
(ºC)

Yield
(%)a

4

25

30

PyAOP/DIEA/DMF

2

50

91

Fmoc-Lys(Boc)-OH

PyAOP/DIEA/DMF

4

25

36

Fmoc-Lys(Boc)-OH

PyAOP/DIEA/DMF

2

50

92

The coupling yield is determined by UV analysis of the Fmoc-deprotection.2.17

terminus of a ααAA was more difficult than coupling at its C-terminus.2.18-2.19 Improved
methods for efficient incorporation of sterically hindered ααAAs into peptide internal
positions will be discussed in Chapter 4 of this dissertation.
After the last amino acid coupling, all peptides were acetylated with acetic
anhydride in DMF. The crude peptides were cleaved from the resin by TFA and purified
by reversed-phase HPLC on a C4 column. All peptides except DPG-3 were purified
using a gradient of water and acetonitrile with 0.05% TFA in each solvent. Peptide
DPG-3, which had the sequence Ac-Glu-Dpg-Tyr-Dpg-Glu-NH2, with no positively
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charged side chains, was purified in more neutral condition with the presence of
triethylammoniun acetate (TEAA) in each eluent (water and acetonitrile). All peptides
were analyzed by analytical HPLC, amino acid analysis, and matrix-assisted laser
desorption ionization mass spectrometry (MALDI).
2.2.3

Conformational Studies by Circular Dichroism
It was hypothesized that the Dpg peptides would adopt extended β-strand

structure and might further associate to form β-sheets. The peptide with a β-sheet
structure usually has a single minimum CD band between 210 and 225 nm and a relative
strong positive band between 190 and 200 nm.2.20-2.22 The CD band intensities of βsheets are typically weaker than those of α-helices. Peptide conformations can be greatly
affected by the presence of organic solvents like TFE and acetonitrile. To keep the CD
analysis conditions comparable with biological environment, the conformational study
of all Dpg peptides and NVA peptides was carried out in buffered aqueous solutions
without any organic modifier.
Peptides DPG-1, DPG-2, and DPG-3 have a similar sequence. The CD spectra of
the three peptides are shown in Figure 2.5. All three peptides displayed similar, but
characteristic CD bands in pH 7.0 phosphate buffer solution: a positive band near
200 nm, a strong negative band at 185-190 nm, and a weak negative band at 230 nm.
Peptide DPG-2 apparently exhibited larger CD intensities than DPG-1 and DPG-3 under
the same conditions. The far UV band at 200 nm was likely an indication of either a βsheet or β-turn.2.23-2.26 The negative band near 230 nm could be indicative of either βsheet or β-turn structures or may be due to the tyrosine aromatic groups.2.26-2.28
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Figure 2.5 CD spectra of DPG-1, DPG-2, and DPG-3 in phosphate buffer. Conditions:
100 µM peptide in 10 mM phosphate buffer, pH 7.0, 20 ºC.
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Figure 2.6 pH-Dependence of the CD spectra of DPG-2. Conditions: 100 µM peptide in
10 mM of phosphate buffer at pH 7.0, 10 mM of acetate buffer at pH 5.0, and 10 mM of
phosphate buffer at pH 2.7, respectively.
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Figure 2.7 Concentration-dependence of the CD spectra of DPG-2. Conditions: peptide
in 10 mM of phosphate buffer with 1 M NaCl, 20 ºC.
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Figure 2.8 Temperature-dependence of the CD spectra of DPG-2. Conditions: 200 µM
peptide in 10 mM phosphate buffer, pH 7.0.
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Figure 2.9 Temperature-dependence of the CD spectra of DPG-5. Conditions: 250 µM
peptide in 10 mM phosphate buffer, pH 7.0.
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Figure 2.10 Temperature-dependence of the CD spectra of DPG-4. Conditions: 250 µM
peptide in 10 mM phosphate buffer, pH 7.0.
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Figure 2.11 CD spectra of NVA-2 and NVA-5 in phosphate buffer. Conditions: 250 µM
peptide in 10 mM phosphate buffer, pH 7.0, 20 ºC.
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Peptide conformational studies using CD mainly depends on analysis of the overall
shape of CD spectra and comparison with standard peptide spectra. These CD spectra,
which had negative band at 190 nm and 230 nm, positive band at 200 nm, were more
likely from β-turn structures.2.25, 2.29 Peptide DPG-2 had lysine and glutamic acid at each
end of the sequence and the oppositely charged side-chain might induce salt bridge in
aqueous solution. The significantly larger ellipticity values for DPG-2 than those of
DPG-1 and DPG-3 might stem from the strong H-bonding in DPG-2, which was
stabilized by side chain interaction between lysine and glutamic acid. To examine this
assumption, the CD measurement of DPG-2 was carried out in three buffer solutions
with different pH values (Figure 2.6). It was observed that DPG-2 possessed strong CD
bands in neutral solution, and when the pH was decreased, there was a systematic
reduction of ellipticity values for both positive and negative bands. This result indicated
reduced secondary structures in low pH buffer solutions, where the carboxylate was
converted to the acid form thus suppressing salt-bridge formation. The salt-bridge effect
might explain why DPG-2 exhibited larger ellipticity values than DPG-1 and DPG-3, in
which both termini contained either lysine or glutamic acid. In the concentration
dependence study of DPG-2, which was carried out in phosphate buffer at pH 7 (Figure
2.7), no conformational transition was observed in measured concentration range. The
main CD bands were unchanged at various peptide concentrations, indicating a relatively
stable secondary structure content in DPG-2. Temperature-dependence study of DPG-2
also showed a stable secondary structure content as indicated by the nearly unchanged
CD bands under measured temperatures (Figure 2.8).
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Peptide DPG-5 had the sequence homologous to DPG-2, except that tyrosine was
replaced by threonine. Surprisingly, the CD spectra of DPG-5 displayed a different
pattern from that of DPG-2 (Figure 2.9). There were a strong minimum at 198 nm and a
weak minimum at 230 nm respectively, indicating that the peptide adopted both
random coil and β-turn or β-sheet like structures.2.27, 2.30 Upon heating, the CD band
intensity at 198 nm became weaker, while the intensity at 230 nm turned stronger. This
kind of trend is usually an indication of increased content of peptide ordered
structures.2.27 Peptide DPG-4 had a longer sequence than other peptides in this study.
The CD spectra of DPG-4 looked very similar to those of DPG-5, with minima at 198
and 228 nm respectively (Figure 2.10). Upon heating, the CD bands from DPG-4
showed the same trend as DPG-5, indicating an increased content of β-turn or β-sheet
and reduced content of random coil.
To study the effect of Dpg residues on short peptide conformational preference,
we synthesized two pentapeptide analogues NVA-2 and NVA-5. Peptides NVA-2 and
NVA-5 had the similar sequence as DPG-2 and DPG-5 respectively, except that each
Dpg residue was replaced by its amino acid analogue L-norvaline (Cα-propylglycine). It
was observed that both NVA-2 and NVA-5 mainly adopted random coil structure as
indicated by the unique negative band at 197 nm (Figure 2.11). The pronounced
difference between the CD spectra of Dpg peptides and Nva peptides indicated that
incorporation of norvaline into short peptides didn’t induce ordered structures, while
incorporation of Dpg residues could significantly affect conformational behavior of the
short peptides. The CD spectrum of DPG-2 looked totally different from that of NVA-2,
where substitution of Dpg residues with norvalines leads to almost total loss of ordered
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structures. In contrast, DPG-5 and NVA-5 gave similar CD spectra, though the CD
spectra of DPG-5 had a weak minimum at 230 nm. From the CD analysis of DPG-5, it
seemed that this peptide contained mainly random coils and a small amount of β-turn or
β-sheet like structures. NVA-5 adopted predominately order less structures that were
indicated by the characteristic CD band. CD analysis of Dpg peptides and Nva peptides
indicated that Dpg residues could impose considerable constraints on peptide backbone
thus induce ordered structure, while the conformational impact of Dpg residues on
peptide backbones was also influenced by other residues in the sequence, such as
tyrosine and threonine. The CD analysis revealed some information about the Dpg
peptide secondary structures, but the CD spectra of β-turns or β-sheets are more difficult
to interpret than those of α-helical peptides. Further study is required for more accurate
structure determination. In fact, these indicative data obtained from CD study will be
employed to assist the peptide solution structural analysis by NMR spectroscopy.
2.2.4

NMR Studies of the Solution Structure of Dpg Peptides
Peptide DPG-2 and DPG-5, which exhibited characteristic CD spectrum features,

were further analyzed by NMR. To keep the NMR study condition consistent with that
in CD study, the peptide samples in NMR experiment were prepared in 90% aqueous
phosphate buffer and 10% D2O. Figure 2.12 and Figure 2.13 show 1D 1H NMR
spectrum of DPG-2 and DPG-5 respectively. The assignment of the 1D spectrum was
made using peak integration, 2D Correlated Spectroscopy (COSY), Total Correlation
Spectroscopy (TOCSY), Nuclear Overhauser and Exchange Spectroscopy (NOESY),
Rotating Frame Overhauser Enhancement Spectroscopy (ROESY), Heteronuclear (1H13

C) Correlated Spectroscopy, and sequence specific procedures described by Wüthrich.2.31
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Figure 2.12 1H NMR of DPG-2. Conditions: 10 mM DPG-2 in 30 mM phosphate buffer
at pH 7; Solvent composition, H2O-D2O (9:1); 400 MHz.
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Figure 2.13 1H NMR of DPG-5. Conditions: 10 mM DPG-5 in 30 mM phosphate buffer
at pH 7; Solvent composition, H2O-D2O (9:1); 300MHz.

42

Table 2.3 NMR parameters of peptide DPG-2 in phosphate buffer.
β
(ppm)

3

JHNCαH
(Hz)

Residue

NH
(ppm)

α
(ppm)

Glu(1)

8.57

4.05

1.93, 2.02

γ 2.30

4.9

Dpg(2)

8.18

-

1.45, 1.55

γ 0.73, 1.05
δ 0.74, 0.82

-

Tyr(3)

7.69

4.48

2.80, 3.15

δ 7.12
ε 6.81

7.1

Dpg(4)

7.79

-

1.81, 1.91

γ 1.15, 1.08
δ 0.94, 0.96

-

Lys(5)

8.04

4.22

1.80, 1.90

γ 1.45
δ 1.70
ε 3.05

7.1

Others
(ppm)

Table 2.4 NMR parameters of peptide DPG-5 in phosphate buffer.
β
(ppm)

3

JHNCαH
(Hz)

Residue

NH
(ppm)

α
(ppm)

Glu(1)

8.39

4.22

1.95, 2.05

γ 2.30

5.7

Dpg(2)

8.29

-

1.75, 1.83

γ 1.15, 1.13
δ 0.88, 0.90

-

Thr(3)

7.72

4.24

4.23

γ 1.21

7.7

Dpg(4)

7.86

-

1.86, 1.93

γ 1.16, 1.19
δ 0.89, 0.90

-

Lys(5)

7.85

4.24

1.82, 1.90

γ 1.46
δ 1.69
ε 2.98

7.1

43

Others
(ppm)

Figure 2.14 Amide-amide region of ROESY spectrum of DPG-2. The NOE data were
obtained from a 400 MHz NMR using a 10 mM sample in phosphate buffer.
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Figure 2.15 Amide-α-hydrogen region of ROESY spectrum of DPG-2. The NOE data
were obtained from a 400 MHz NMR using a 10 mM sample in phosphate buffer.
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Figure 2.16 NOE connectivities on the backbone of DPG-2. The NOE data were
obtained from a 400 MHz NMR using a 10 mM sample in phosphate buffer. Strong
NOEs are indicated by red arrows, and blue arrows represent relatively weak NOEs.
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Figure 2.17 Amide-amide region of ROESY spectrum of DPG-5. The NOE data were
obtained from a 400 MHz NMR using a 10 mM sample in phosphate buffer.
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Lys-α
Thr-α
Thr-β

Figure 2.18 Amide-α-hydrogen region of ROESY spectrum of DPG-5. The NOE data
were obtained from a 400 MHz NMR using a 10 mM sample in phosphate buffer.
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Figure 2.19 1H NMR of amide NH in DPG-2 at various temperatures. Conditions: 10
mM peptide in 30 mM phosphate buffer; 500 MHz.
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In the sequential assignment procedure, spin systems of common L-amino acids like
tyrosine and lysine were first assigned based on COSY, TOCSY, and peak integrations.
Connectivities between the 1H spin system of sequentially neighboring monomeric units
were established by heteronuclear COSY and NOEs. The resulting segments of
neighboring 1H spin systems were then matched against the corresponding segments in
the sequence of the peptide chain to obtain sequence-specific assignments. The relevant
chemical shifts of protons in DPG-2 and DPG-5, and coupling constants 3JHNCαH are
summarized in Table 2.3 and Table 2.4 respectively. Inspection of the chemical shifts
revealed that all three Cα protons on the backbone of DPG-2 were well separated, while
the three Cα protons in DPG-5 were positioned very close to each other. The NMR input
for peptide secondary structure analysis depends primarily on the

1

H-1H NOE

measurements which detect the interproton distance of 5Å or less. In the proposed β-sheet
structure illustrated in Figure 2.3, the interstrand distance of several pairs of protons, such
as dNN(Dpg2, Dpg4) and dαN(Lys5, Dpg2) would be relatively short and should be detected
by NOE measurements. Figure 2.14 and Figure 2.15 illustrated the extended ROESY of
amide-amide region and amide-α-hydrogen region of DPG-2. The cross peaks that were
characteristic of the proposed β-sheet structure were not observed. Instead, there were a
number of sequential NOEs in the spectra, which were usually displayed by helical
structures. The NOE connectivities on DPG-2 backbone were indicated in Figure
2.16. Besides the sequential NOEs, there were some interesting NOE interactions
between protons on certain residue side-chains, such as tyrosine aromatic protons
and Dpg (2) γ and δ protons. This kind of interaction might stem from a folded structure
that caused the side-chains on adjacent residues to be close to one another. The finger
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print regions of ROESY of DPG-5 were displayed in Figure 2.17 and Figure 2.18
respectively. There were a number of sequential NOEs in amide-amide region. However,
currently it is impossible to assign the amide-α-Hs for DPG-5 due to overlapped peaks of
α-H of lysine, threonine, glutamic acid, and β-H of threonine. The unavailable
assignments of the individual amide-α-H cross peak makes NOE information needed for
DPG-5 structure determination insufficient.
Dyson and Wright reported several NMR criteria for characterizing peptides with
β-turn populations.2.32 These criteria include depressed temperature coefficients of Hbonded amide protons and characteristic NOE connectivities, such as d NN (i, i + 1)

Table 2.5 Temperature coefficient of residues in DPG-2.a
DPG-2 Residue

Obsd. Temp. Coefficient Reported Temp. Coefficient
(ppm/K × 103)b
(ppm/K × 103)

Glu

-7.0

-6.0

Dpg(2)

-7.7

-

Tyr

-5.5

-8.0

Dpg(4)

-3.4

-

Lys

-8.3

-7.2

NH(6)(upfield)

-6.1

-

NH(6)(downfield)

-5.6

-

a

The calculation was carried out using the NH chemical shift data obtained
between 278-313K.
b
The peptides adopted random coil under measured conditions. 2.33
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between residue 3 and 4 of the turn and d αN (2, 3), d αN (2, 4) NOE
connectivities. Temperature coefficients represent the relative change rate of NH
chemical shift over a range of measured temperature.

The temperature

coefficients for residues in DPG-2 were calculated using the data obtained between
278K and 313K (Figure 2.19; Table 2.5). The depressed temperature coefficient
indicates that the amide proton is protected from exchange to some degree. In the
ROESY spectrum of DPG-2, the observed crosspeaks dαΝ(Glu1, Dpg2) (Figure 2.15)
and dNN(Dpg2, Tyr3) (Figure 2.14) indicates a type II β-turn structure with an
intramolecular H-bond between the acetyl carbonyl oxygen and the tyrosine NH. The
temperature coefficient of Tyr NH was substantially smaller than the reported value
from tyrosine in random coils,2.33 indicating that tyrosine NH in DPG-2 might be
involved in H-bonding. The dNN(Tyr3, Dpg4) crosspeak and depressed temperature
coefficient of the Dpg4 NH suggested another β-turn in residue Glu1-Dpg4. Though
there are no reported temperature coefficients for Dpg residues, the pronounced
difference between Dpg (2) and Dpg (4) NH temperature coefficients suggested that
the NH of Dpg4 is H-bonded. Based on the NMR data and CD results, a backbone
conformation consists of consecutive β-turn structure, namely a type II-β turn from the
acetyl group to Tyr3 and a type I’ β-turn from Glu1 to Dpg4, was generated and refined
by energy minimization program using SYBYL.2.34 This computer generated solution
structure of DPG-2 was consistent with NMR data (Figure 2.20). The H-bonds are
indicated by dotted lines. In the model the aromatic ring of tyrosine and the prochiral
(S) side chain of Dpg2 were on the same side of the turn and they were close to each
other, consistent with the data suggesting the side-chain to aromatic ring NOE
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Figure 2.20 Minimized molecular model of populated folded structure of DPG-2
in aqueous solution. Hydrogen bonds are indicated by doted lines.
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connectivities. Also, the side chains of glutamic acid and lysine are close in space,
consistent with a salt bridge interaction that further stabilizes the β-turn structure in
DPG-2, as shown in the pH-dependence CD of DPG-2. The consecutive β-turn structure
observed in DPG-2 was a short section of a left-handed 310-helix which was
characterized by short sequential and medium range NH NOE connectivities.
Dpg residues could adopt both extended and helical conformation, depending on
peptide sequence, length, and environmental factors.2.35 It has been reported that Dpg
residues are likely to adopt C5 conformation in the sequence where flanking residues
have a strong tendency to adopt extended structures. Meanwhile, in helix-promoting
situation, Dpg could be easily accommodated into a helical conformation2.33
Indeed the conformation energy of extended and helical structure in Dpg
derivatives were often close to each other, subtle sequence modification could affect the
peptide conformational preference.
2.3

Conclusions
Cα,α-disubstituted amino acids have been recognized as a means of introducing

backbone conformation constraints in peptides. In this work, several peptides containing
Dpg and its analogous, L-norvaline, were synthesized for conformational studies. It was
found that at elevated temperatures PyAOP was a powerful coupling reagent for
incorporating Dpg residues into peptide internal positions. Systematic structural studies
on Dpg peptides were performed by CD and NMR techniques. All Dpg peptides
displayed certain content of order secondary structures, while the Nva peptides adopted
mainly random coils. It was observed that in peptide DPG-2, Ac-Lys-Dpg-Tyr-DpgGlu-NH2, Dpg residues adopted helical structures, instead of extended structures. It was
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interesting to note the conformational difference between DPG-2 and DPG-5 where
substitution of the central residue substantially changed the conformational preference of
the peptide. Though Dpg residues could impose considerable constraints on peptide
backbone, the conformation of the Dpg peptides was affected by the whole sequence, not
just a single residue. In fact, the local structural behavior of Dpg residues was context
dependent. Dpg residues were likely to adopt helical conformation in a helix-promoting
sequence, while they tended to adopt extended C5 structures in a sequence where the
residues had a strong preference to extended conformation. It seemed that tyrosine was
likely to adopt left-handed helical conformation and thus could be easily fitted into a
type I’ β-turn structure, while threonine which had a branched side chain didn’t favor
helical structures in the present sequence context. The results bore this out in that DPG-2
possessed consecutive β-turns, while DPG-5 mainly adopted random coil structure. It
was also observed in this study that side chain interactions between oppositely charged
groups could strengthen the intramolecular H-bonding and consequently stabilize the
Dpg peptide secondary structures. In our recent study of conformational behavior of
NVA-2, a peptide analogue of DPG-2, the peptide showed a strong tendency to
polymerization in a neutral phosphate buffer even under diluted concentrations (~200
µM). This result may indicate a β-sheet formation in NVA-2 resulting from cross-strand
H-bonding as predicated for DPG-2. If NVA-2 had the proposed aggregation in aqueous
solution, structural studies could reveal the impact of norvaline and dipropylglycine on
peptide conformation preference, which in turn will facilitate the design of β-strand
mimics containing ααAAs with/without their amino acid analogous.
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2.4

Experimental

2.4.1

Synthesis of Nα-protected ααAAs

KCN, (NH4)2CO3

O
R

R

R
O

MeOH/H2O
r.t.a or refluxb

5N NaOH/Refluxa

R
NH

HN

R
+

b

or 6N KOH
175 oC, 15psi

O

2.1a
2.1b

H3N

CO22.2a
2.2b

Fmoc-Cl

TMS-Cl
DIEA

R
a R = CH2CH2CH3
b R = CH2CH(CH3)2

R

FmocHN

R
CO2H
2.3a
2.3b

Figure 2.21 Synthesis of Fmoc-ααAAs with Bucherer-Bergs method.
Heptane-4-spiro-5’-hydantoin (2.1a)
A solution of 4-heptanone (5.0 g, 43.8 mmol), potassium cyanide (6.0 g, 91.9
mmol), and ammonium carbonate (9.3 g, 96.3 mmol) in methanol (25 mL) and water (25
mL) was heated at 50 ºC in a capped vessel for 36 hours. The precipitated solid was
filtered and washed with small portion of water and dried in air. The hydantoin was
obtained as off-white powder (6.6 g, 82%). 1H (250 MHz, CD3SOCD3) δ: 10.52 (s, 1H),
7.84 (s, 1H), 1.62-1.43 (m, 4H), 1.42-1.22 (m, 2H), 1.21-1.02 (m, 2H), 0.97-0.85 (t, 6H).
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2,2-Dipropylglycine (2.2a)
The hydantoin 2.1a (2.5 g, 13.6 mmol) were suspended in 5 N NaOH (27.2 mL,
136.0 mmol) and heated under reflux for 40 hours. The mixture was cooled, acidified to
pH 6.5 with concentrated hydrochloric acid and filtered. The filtrate was dried by
removal of the solvent under vacuo and washed with small portion of acetone to remove
the unreacted hydantoin. Both the filtrate residue and the solid which precipitated out
upon acidification were extracted with warm ethanol for several times. Pure white
dipropyl glycine was obtained by removal of ethanol under vacuum condition (1.7 g,
78%). 1H ( 250 MHz, CD3SOCD3) δ: 7.34(s, 2H), 1.55-1.10 (m, 8H), 0.88-0.78 (t, 6H).
Να-(9-Fluorenylmethoxycarbonyl)-2,2-dipropylglycine (2.3a)
To a solution of 2.2a (5 g, 31.4 mmol) in dry DCM (75 mL), trimethylsilyl
chloride (7.9 mL, 62.8 mmol) was added in one portion and the mixture was heated
under reflux for 6 hours. The mixture was cooled in an ice bath, then N,Ndiisopropylethyl amine (9.8 mL, 56.5 mmol) and Fmoc chloride (7.5g, 28.9 mmol) were
added. The solution was stirred with cooling for 30 minutes and then warmed to room
temperature. After stirring overnight, the mixture was concentrated under reduced
pressure, the residue taken up in 2.5 % aqueous NaHCO3 (220 mL), washed with ethyl
ether (2 x 120 mL). The ether layers were back washed with 2.5% aqueous NaHCO3
(100 mL) and the combined aqueous layers were acidified by 1N HCl to pH 2.0 in the
presence of ethyl acetate (170 mL). After separation, the aqueous layer was again
extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over
MgSO4 and concentrated under reduced pressure, giving white solid product 2.3a (7.5 g,
68%). 1H (250 MHz, CD3SOCD3) δ: 10.68 (s, 1H), 7.91-7.88 (d, 2H), 7.71-7.69 (d, 2H),
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7.44-7.29 (m, 4H), 6.95 (s, 1H), 4.28-4.21 (m, 3H), 1.76-1.74 (m, 4H), 1.20-1.10 (m,
2H), 0.86-0.82 (m, 6H). Anal. Calcd for C23H27NO4 (381.45): C, 74.42; H, 7.13; N, 3.67.
Found: C, 72.58; H, 7.13; N, 3.80.
2,6-Dimethyl heptane-4-spiro-5’-hydantoin (2.1b)
By using the similar procedure described for 2.1a, the mixture was heated under
reflux for 60 hours and the resultant white precipitate was isolated by filtration and
washed with small portions of water. Yield: 45%. 1H (250 MHz, CD3SOCD3) δ: 10.60
(s, 1H), 7.85 (s, 1H), 1.63-1.38 (m, 6H), 0.88-0.78 (m, 12H).
2,2-Diisobutylglycine (2.2b)
The hydantoin 2.1b (2.0 g, 9.4 mmol) was suspended in 6 N KOH (19 mL, 113.0
mmol) in a pressure-proof vessel and heated at 175 ºC and under 15 psi for 48 hours. By
using the same work up procedure described for 1a, diisobutyl glycine was obtained as
white solid (0.85 g, 50%).

1

H (250 MHz, CD3SOCD3) δ: 6.67 (s, 2H), 1.80-1.36 (m,

6H), 0.87-0.76 (m, 12H).
Να-(9-Fluorenylmethoxycarbonyl)-2,2-diisobutylglycine (2.3b)
Compound 2.3b was prepared using the same procedure described for 2.3a.
Yield, 56%. 1H (250 MHz, CD3SOCD3) δ: 13.25 (s, 1H), 7.90-7.87 (d, 2H), 7.70-7.68
(d, 2H), 7.44-7.34 (m, 4H), 6.49 (s, 1H), 4.32-4.31 (m, 3H), 2.03-1.98 (m, 2H), 1.601.47 (m, 4H), 0.81-0.78 (m, 12H). Anal. Calcd for C25H31NO4 (409.50): C, 73.32; H,
7.63; N, 3.42. Found: C, 73.15; H, 7.40; N, 3.28.
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2.4.2

Synthesis of Peptides
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a. Fmoc removal

b. (Ac)2O, DIEA / DMF
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Ac-Glu-Dpg-Tyr-Dpg-Lys-NH2
(DPG-2)

Figure 2.22 Assembly of peptide DPG-2.
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All peptides synthesis was carried out on PerSeptive Biosystem 9050 synthesizer
using Fmoc-PAL-PEG-PS resin as illustrated in the synthesis scheme for DPG-2. The
Fmoc group was removed by 1,8-diazabicyclo[4.5.0]undec-ene (DBU)-piperidine-DMF
(2:20:80) solution and the excess amino acids (4 equiv.), PyAOP(4 equiv.), and DIEA(8
equiv.) were employed in the coupling process. To enhance the coupling with ααAAs, a
water jacket was utilized to keep the column at 50 ºC. The acetylation of the peptide N
terminus was performed by manual synthesis. The peptide bound to resin was treated
with excess 0.2 M of Ac2O in 0.28 M of DIEA/DMF solution (16 equiv.) for 2 hours.
After rinsing with DMF and DCM and drying under high vacuum for 4 hours, the resin
was treated with standard cleavage solution (trifluoroacetic acid-triisopropylsilanewater: phenol, 8.8:0.2:0.5:0.5) to cleave the peptide from the resin. The resulting
solution was diluted with cold 40% acetic acid solution, washed with cold diethyl ether
(5 x 40 mL), and lyophilized to yield to crude peptides.
2.4.3

Peptide Purification and Characterization
The crude peptides were purified by reverse phase HPLC using Waters Deltapak

C4 column (15 µm, 300 A, 25 x 100mm). The flow rate was 1 mL/Min for analytical
HPLC and 10 mL/min for preparative HPLC. For all peptides except peptide DPG-3,
solvent A was 0.05% TFA in water, solvent B was 0.05% TFA in acetonitrile. For
peptide DPG-3, solvent C and D was utilized for purification. Solvent C was 0.025M
TEAA in water, and solvent D was 0.025M TEAA in acetontrile/water (90:10) solution.
The identity and purity of the peptides was confirmed by quantitative amino acid
analysis and matrix-assisted laser desorption/ionization mass spectrometry.
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Peptide DPG-1 (C39H68N6O6)
Preparative HPLC purification was carried out using a linear gradient from 5% to
50% B over 50 minutes, tR = 24.5 min., overall yield 55%; MALDI (M + H)+ m/z calcd
762.0, obsd 761.9.
Peptide DPG-2 (C38H63N6O8)
Preparative HPLC purification was carried out using a linear gradient from 5% to
50% B over 60 minutes, tR = 26.7 min., overall yield 46%; MALDI (M + H)+ m/z calcd
761.9, obsd 761.9.
Peptide DPG-3 (C37H58N6O10)
Preparative HPLC purification was carried out using a linear gradient from 5% to
60% C over 60 minutes, tR = 25.7 min., overall yield 47%; MALDI (M-H)- m/z calcd
761.9, obsd 761.8.
Peptide DPG-4 (C57H106N10O12)
Preparative HPLC purification was carried out using a linear gradient from 10%
to 80% B over 65 minutes, tR = 38.7 min., overall yield 18%; MALDI (M + H)+ m/z
calcd 1181.5, obsd 1181.5.
Peptide DPG-5 (C33H61N6O9)
Preparative HPLC purification was carried out using a linear gradient from 5% to
50% B over 50 minutes, tR = 27.3 min., overall yield 35%; MALDI (M + H)+ m/z calcd
700.9, obsd 700.8.
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Peptide NVA-2 (C38H51N6O8)
Preparative HPLC purification was carried out using a linear gradient from 5% to
50% B over 50 minutes, tR = 24.9 min., overall yield 58%; yield 58%; MALDI (M + H)+
m/z calcd 720.8, obsd 720.8.
Peptide NVA-5 (C33H49N6O9)
Preparative HPLC purification was carried out using a linear gradient from 5% to
50% B over 50 minutes, tR = 25.0 min., overall yield 55%; MALDI (M + H)+ m/z calcd
674.7, obsd 674.8.
2.4.4

Circular Dichroism
Circular dichroism measurements were performed on a (+)-camphor sulfonic

acid calibrated Aviv 60DS spectrophotometer. The samples were prepared as stock
solutions in buffer and diluted to the desired concentration in proper solution for
measurements. The CD measurements were recorded over a 250-180 nm range using a
quartz cell of 1 mm path length, 1 nm bandwidth, 20 nm/min scan speed, and a time
constant of 0.5 s. Molar ellipticity was calculated using the formula [θ] =
[θ]obs(MRW/10cd), where [θ]obs was the mean residue molecular weight of the peptide
(molecular weight divided by the number of peptide bonds), c was the concentration of
the sample in mg/mL, and d was the optical pathlengh of the cell in cm. All spectra were
corrected for buffer (or solvent) contributions and presented in unit of molar ellipticity.
2.4.5

Nuclear Magnetic Resonance
The NMR studies of Peptide DPG-2 and DPG-5 were performed on Bruker

ARV-300, Avanee 400, and AM-500 NMR spectrometers. The samples contained 11.5
mM peptide in 30 mM phosphate buffer, 90:10 H2O/D2O. All spectra of peptides were
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referred to sodium 3-(trimethylsiyl)propionate-2, 2, 3, 3-d4 (TSP). The 3JNα values were
determined from the amide signals in the 1D spectra over the temperature range of 278318 K (every 5 K). These 3JNα values didn’t vary significantly with temperature. The
2-D scalar COSY, TOCSY, ROESY experiments were run in phase-sensitive mode
using quadrature detection by time-proportional phase incrementation of initial pulse.
TOCSY experiment was carried out using a mixing time of 80 ms, and a mixing time of
200 ms was employed for ROESY experiment. Amide exchange experiments were
repeated twice, and the average results were reported. Plots of temperature (278-318 K)
vs peak position (ppm) for each of the amide protons were made for temperature
coefficient determination.
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CHAPTER 3
SYNTHESIS OF STERICALLY HINDERED Cα,α-DISUBSTITUTED AMINO
ACIDS FROM NITROACETATE*
3.1

Introduction
The discovery of Cα,α-disubstituted amino acids (ααAA, Figure 3.1) in

biological systems and their propensity to induce secondary structure has resulted in an
increased interest in de novo peptide design containing ααAAs.3.1-3.6 The prototype of
ααAA, α-aminoisobutyric acid (Aib), is a naturally occurring amino acid observed in a
number of antibiotic peptides, such as alamethicin, tricorzianine, emerimicin, and
zerraminic. 3.7-3.10 All these linear peptides contain 5-8 Aib in their 15-20 residue

R R
H2N

CO2H

Aib R = CH3
Dpg R = CH2CH2CH3
Dbzg R = CH2Ph

Figure 3.1 Structure of representative ααAAs.

*Reprinted in part with permission from The Journal of Organic Chemistry, 2001,
Volume 66, pages 7118-7124; Fu, Y.; Hammarström, L. G. J.; Miller, T. J.; Fronczek, F.
R.; McLaughlin, M. L.; Hammer, R. P., Sterically Hindered Cα,α-Disubstituted α-Amino
Acids: Synthesis form α-Nitroacetate and Incorporation Into Peptides. Copyright 2001
American Chemical Society.
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sequences. Extensive conformational studies of both natural and synthetic Aib peptides
have established the strong preference of this residue for 310/α-helical sructure.3.11-3.16
Higher alkyl analogous of Aib, such as Cα,α-dipropylglycine (Dpg), favor
extended structure, especially in the homo-sequence peptides.3.17-3.20 Meanwhile, more
sterically hindered ααAAs, such as Cα,α-dibenzyl glycine (Dbzg), have shown a
overwhelming preference to the extended C5 conformation.3.21-3.22 Unlike Aib, sterically
demanding ααAAs have not been commonly used in peptide design. This is mainly due
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R
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R
COOH

3.1

Figure 3.2 Synthesis of ααAAs with Strecker method and Bucherer-Bergs method.
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to the difficulty in ααAA preparation and in peptide assembly containing hindered
ααAAs. The most common methods of ααAA synthesis include the Strecker and
Bucherer-Bergs method (Figure 3.2).3.23-3.24 In Strecker method, amino acid is prepared
from hydrolysis of amino nitrile which is obtained by reacting ketone with ammonium
salt and cyanide. The Bucherer-Berg synthesis is characterized by formation of a
hydantoin, which is subquently cleaved under basic condition to yield the free ααAA
We have found the Bucherer-Berg method convenient and effective for preparation of a
number of hydantoins that can be hydrolyzed to ααAAs. Also we and others have
developed milder methods for cleaving hydantoins which are functionalized by tbutyloxycarbonyl groups.3.25-3.26 However, several more sterically hindered hydantoins,
including dibenzyl hydantoin (R = Bn), have been impossible to hydrolyze to the free
amino acids, even under the most extreme condition. For example, hydrolysis of
dibenzyl hydantoin with either strong base (6 M KOH, 20 psi, 180 ºC, 2 days) or strong
acid (10 N HBr, reflux, 2 days) gave staring material as the only isolable product. Also,
it has been found that the Bucherer-Bergs route cannot be extended to a number of
noncyclic

difunctionalizedketones,

such

as

1,3-dihydroxy

2-propanone,

4-

oxoheptanedinitrile, and 1,5-diamino-3-pentanone, due to their resistance to hydantoin
formation.3.27 These and other limitation of the hydantoin approach have led to the
development of alternative synthesis of ααAAs, including glycine anion and cation
equivalents.3.28-3.30
Nitroacetate esters have long been recognized as potentially usefully synthetic
intermediate for the preparation of amino acids as well as other biologically significant
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compounds, such as amino alcohols, nitro amines, and carbohydrate derivatives, etc.3.31
In nitroacetate esters, the presence of the active methylene group makes these esters
unique intermediates for the formation of carbon-carbon bonds. Alkylation of
nitroacetate esters have usually resulted in racemic monoalkylations, and the
predominant products were often results of C-and/or O-alkylation.3.31-3.35 Figure 3.3
shows the equilibrium of the anions of nitroacetate ester. The previously reported Calkylation of ethyl nitroacetate with benzyl bromide employed an inorganic base, and the

Base
O2N CH2 CO2R

O

O
N CH CO2R
O

N CH CO2R
O

Figure 3.3 The equilibrium between anions of nitroacetate ester.

the reaction tool a prolonged time.3.36 Electrochemically generated anions have also been
used on a small scale to perform mono- and dialkylations of nitroacetate esters.3.37 In this
study we report an efficient route for preparation of sterically hindered ααAAs via
alkylation of nitroacetate. The strategy and conditions proposed herein employ the
commercially available ethyl nitroacetate 3 along with 2 equiv each of a tertiary amine
base and an electrophile to provide a variety of novel Cα,α-dialky nitroacetate esters
(Figure 3.4). Furthermore, methods for preparing Nα-Fmoc-protected ααAAs, including
tetrafunctional ααAAs, suitable for solid-phase peptide synthesis are elaborated.
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Figure 3.4 Dialkylation of ethyl nitroacetate.

3.2

Results and Discussion
We have found that treatment of ethyl nitroacetate with 2 equiv of DIEA in the

presence of catalytic amounts of tetralkylammonium salts, followed by the addition of an
activated alkyl halide or Michael acceptor, gave the disubstituted nitroacetate ester in
good to excellent yields (Table 3.1). A number of bases have been tried for the
deprotonation, where DIEA gave the best result. DIEA was employed based on evidence
which suggests that ethyl nitroacetate anion exhibits high nucleophilic reactivity in the
presence of a quaternary ammonium cation that does not tend to form a strong ion
pair.3.37 The reactivity of the anion was further increased when a catalytic amount of
tetraalkylammonium salt was added to the reaction. The benzyl bromides gave rapid
conversion to dialkylated products 3.4 in a matter of minutes to hours. Reactions were
initially exothermic-benzyl bromides having electron-withdrawing substituents (Table
3.1, entries 2-4) needed to be cooled initially to control the reaction. When the reaction
was finished, a large mount of diethyl ether was added to the reaction mixture to
precipitate out the ammonium salt formed between DIEA and HBr. Unlike benzyl
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Table 3.1 Alkylation of ethyl nitroacetate to Cα,α-dialkylated nitroacetate.
Entry

Electrophile

Time (h)

Temp (ºC)

Prod. No.

Yield %a

1

PhCH2Br

1

25-60b

3.4a

63

2

p-O2NPhCH2Br

2

0-25

3.4b

75

3

p-NCPhCH2Br

2

0-25

3.4c

82

4

p-CH3O2CPhCH2Br

2

0-25

3.4d

72

5

(CH3)3CO2CCH2Br

24

50

3.4e

79

6

CH2=CHCH2Br

24

60

3.4f

tracec

7

CH2=CHCH2I

24

60

3.4f

45

8

CH2=CHSO2Ph

30

25

3.4g

70

9

CH2=CHCO2t-Bu

48

25

3.4h

89

10

CH2=CHCN

48

25

3.4i

87

a

All percentage yields refer to isolated, analytically pure products.
Spontaneous exotherm to 60 °C.
c
Major product is monoallylated product, ethyl 2-nitro-4-pentenoate.
b

bromides, dialkylation with tert-butyl 2-bromoacetate (Table 3.1, entry 5) required
longer reaction time at slightly elevated temperature (50 ºC) to provide 3.4e in 79%
yield. Allyl bromide gave only trace amounts of the diallylated product, ethyl 2,2bis(allyl)-2-nitroacetate (3.4f), even after prolonged reaction times and heating. The
major product of this reaction was the mono-C-allylated derivative, ethyl 2-nitro-4pentenoate (65%). In order to improve the yield, allyl iodide was tried as the electrophile
for the dialkylation under different reaction conditions, including in several different
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solvents (THF, DMF, and MeCN), and in the presence of different catalysts, including
tetrabutylammonium

bromide

and

tetraethylammonium

bromide,

and

tetrabutylammonium iodide. It was observed that allyl iodide in DMF with the presence
of tetrabutylammonium iodide gave highest yield (45%), however, the product was still
admixed with monoallylated ester. In this study, a number of activated alkenes,
including phenyl vinyl sulfone, tert-butyl acrylate, and acrylonitrile, were employed for
the double Michael-type addition to ethyl nitroacetate.3.27 These reactions were carried
out in MeCN at room temperature and gave the tetrafunctional nitroesters in good yields
(Table 3.1, entries 8-10).
The high yields for these dialkylation reactions make this a particularly viable
route to symmetrically substituted ααAAs (vide infra) with or without side chain
functionality. As examples of the utility of these α-amino acid precursors, the dibenzyl
derivative 3.4a and di-tert-butyl acetate derivative 3.4e were converted to Nαfluorenylmethyloxycarbonyl (Fmoc)-protected Cα,α-dibenzylglycine (Dbzg) 3.7a and
2,2-bis(tert-butylcarboxymethyl)glycine

(Bcmg(OtBu)2-OH)

3.7e,3.27

respectively

(Figure 3.5). First, several methods were investigated for reduction of the nitro group to
an amino group. Nitro ester 3.4a was readily reduced with Zn/acetic acid to afford the
amino ester 3.5a in high yield (Table 3.2, entry 1). Results for catalytic hydrogenation
approaches to reduce the nitro group were mixed. Reduction of the nitro group of Cα,αdisubstituted nitro triester 3.4h, an analogue of 3.4e, with hydrogen (50 psi) over T-1
Raney Ni afforded the desired amino triester 3.5h in excellent yield (Table 3.2, entry 4).
In contrast, Pd/C-catalyzed hydrogenation or catalytic hydrogen transfer with
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Figure 3.5 Synthesis of Nα-Fmoc-protected sterically hindered ααAAs.

ammonium formate in presence of Pd resulted in almost quantitative conversion of 3.4h
to the corresponding hydroxylamine 3.6h (Table 3.2, entries 5 and 6). Similarly catalytic
transfer hydrogenation of 3.4a also produced the hydroxylamine product 3.6a (data not
shown). It has been suggested that Pd catalysis is preferable for partial reduction of
aliphatic nitro groups to hydroxylamines.3.38-3.39 Boger et al. reported hydrogenation of
tertiary aliphatic nitro groups over a variety of catalysts.3.40 They found that
hydrogenation over Raney Ni provided the amino derivatives with variable amounts of
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Table 3.2 Reduction of Cα,α-disubstituted nitro esters.
Entry

Nitro ester

Conditionsa

Product

Yield %b

1

3.4a

Zn/AcOH

3.5a

81

2

3.4e

H2/Raney Ni

3.5e

92

3

3.4h

H2/Raney Ni

3.5h

92

4

3.4h

H2/10% Pd-C

3.6h

97

5

3.4h

HCO2NH4,10% Pd-C

3.6h

97

a

Hydrogenation over Pd or Ni were carried out in hydrogenation flask at 50 psi;
Reduction with Zn/AcOH or HCO2NH4 in the presence of Pd-C was performed in a
regular round bottom flask.

b

All yields refer to isolated pure products.

corresponding hydrocarbon from loss of the nitro group, while reduction using H2-Pd/C,
HCO2NH4-Pd/C, and H2-PtO2 afforded mixtures including the hydroxylamine and
hydrocarbon. The observed partial reduction of Cα.α-disubstituted nitro ester 3.4h into
the hydroxylamine ester may be attributed to the relatively low activity of Pd catalysts
and the intramolecular hydrogen bonding which enhanced the stability of the
hydroxylamine derivative (Figure 3.6). On the basis of these experimental results,

O
N
H
R

H

O
R

O

Et

Figure 3.6 Intramolecular hydrogen bonding in hydroxylamine.
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reduction of nitro triester 3.4e was carried out using H2/Ni at 50 psi, and the desired
amino ester 3.5e was obtained as a clear crystalline crystalline solid in excellent yield
(Table 3.2, entry 3).3.27
To make the desired Fmoc-protected amino acids, the ester of the α-carboxylate
must first be removed. For amino ester 3.5a this was readily accomplished by
saponfication under strong basic conditions (2M KOH) in refluxing H2O-EtOH (v/v,
2:1) to give the free ααAA 3.1a in 88% yield (Figure 3.5). Unlike saponfication of 3.5a,
hydrolysis of the ethyl ester of triester 3.5e required more precise conditions to avoid
concurrent tert-butyl ester hydrolysis. Selective hydrolysis was realized by treatment of
3.5e with 3 equiv of lithium hydroxide in H2O-EtOH (v/v, 1:2) at 50 ºC to give the side –
chain protected ααAA 3.1e in 82% yield.3.27 Acid-catalyzed hydrolysis of 3.5e with
HCl, nucleophilic dealkylation, and saponfication using KOH failed to selectively
hydrolyze the ethyl ester. The low selectivity of ethyl vs tert-butyl ester hydrolysis in
this compound is most likely due to the steric congestion of the ethyl ester resulting form
its proximity to the quaternary α-carbon. The free ααAAs are Nα-protected to allow for
solid-phase peptide synthesis. Protection of the amine with Fmoc-Cl using an in situ
silylation procedure3.41 provided Nα-(9-Fluorenylmethoxycarbonyl)-2,2-dibenzylglycine
(Fmoc-Dbzg-OH, 3.7a) in 80 % yield and Nα-(9-Fluorenylmethoxycarbonyl)-2,2bis(tert-butyl-carboxymethyl)glycine (Fmoc-Bcmg(OtBu)2-OH, 3.7e) in 71% yield. The
synthetic route allows facile synthesis of sterically hindered ααAAs, even those with
sensitive side-chain functionality, in good yields (57% for 3.7a from 3.4a, 54% for 3.7e
from 3.4e).
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3.3

Conclusions
In this study, we have presented a new strategy for preparation of sterically

hindered ααAAs via mild dialkylation of nitroacetate. The method has been shown to be
successful for the synthesis of highly sterically encumbered ααAAs (Fmoc-Dbzg-OH),
as well as the synthesis of chemically sensitive ααAAs, such as the Να- and side chainprotected tetrafunctional derivatives (Fmoc-Bcmg(OtBu)2-OH). Both ααAAs can be
directly used in solid-phase peptide synthesis. This methodology should prove
invaluable for the preparation of previously unavailable ααAAs with and without side
chain functionality.
3.4

Experimental

3.4.1

Cα,α-Dialkylated Nitroacetate

R-X
OEt

O2N
O

+

or
EWG

DIEA, R'4N Y
DMF or CH3CN

R
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O
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3.4d
3.4e
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R
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R = p-CH2PhNO2
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R = CH2CH2SO2Ph
R = CH2CH2CO2C(CH3)3
R = CH2CH2CN

Figure 3.7 Synthesis of dialkylated ethyl nitroacetate.
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Ethyl 2-benzyl-2-nitro-3-phenylpropanoate (3.4a)
To a solution of ethyl nitroacetate 3.3 (1.0 g, 7.51 mmol) in dry DMF (5 mL) was
added DIEA (2.0 g, 15.4 mmol) and Bu4N+Br– (0.24 g, 0.75 mmol). To this clear yellow
solution, benzyl bromide (2.6 g, 15.4 mmol) was added and the reaction spontaneously
warmed to 60 °C over 5 min. After 20 min., DIEA•HBr precipitated out of solution.
After 1 h, the solution was filtered to remove DIEA•HBr, the salt was washed with Et2O
(100 mL), and the combined filtrates were washed with H2O (5 x 50 mL). The organic
layer was dried (Na2SO4) and evaporated at 0 OC to provide a yellow oil, which was of
sufficient purity to be used in further reactions or could be purified to homogeneity by
silica gel chromatography using Et2O-pentane (1:4) to provide a white solid. Yield, 1.48
g (63%); mp 81-82 OC; 1H NMR (250 MHz, DMSO-d6) δ 7.38-7.22 (m, 10H), 4.10 (q, J
= 7.1 Hz, 2H), 3.52 (d, J = 14.2 Hz, 2H), 3.46 (d, J = 14.2 Hz, 2H), 1.07 (t J = 7.1 Hz,
3H);

13

C NMR (60 MHz, CDCl3) δ 166.5, 133.4, 130.3, 128.8, 128.0, 97.4, 62.9, 40.2,

13.7; HRMS (FAB) calcd for C18H19NO4 (M + H)+ 314.1392, found 314.1395. Anal.
Calcd for C18H19NO4: C, 68.99; H, 6.11; N, 4.47. Found: C, 69.09; H, 5.94; N, 4.32.
Ethyl 2-nitro-2-(4-nitrobenzyl)-3-(4-nitrophenyl)propanoate (3.4b)
To a solution of ethyl nitroacetate 3 (1.0 g, 7.51 mmol) in dry DMF (5 mL) was
added Bu4N+Br- (0.24 g, 0.75 mmol) and 4-nitrobenzyl bromide (3.3 g, 15.4 mmol). To
this cooled solution, DIEA (2.0 g, 15.4 mmol) was added dropwise and the solution was
allowed to stir for 2 hrs. The resulting solution was diluted with diethyl ether (100 mL)
and washed successively with 1N HCl (2 x 15 mL), saturated aqueous sodium carbonate
solution (2 x 15 mL), and water (5 x 15 mL). The solvent was removed in vacuo and the
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resulting light yellow solid was recrystallized from ethanol to provide 2.27 g (75%) of
3.4b as white crystals. mp 194-196 OC; 1H NMR (250 MHz, DMSO-d6) δ 8.21 (d, J =
8.74 Hz, 4H), 7.51 (d, J = 8.74 Hz, 4H), 4.11(q, J = 7.1 Hz, 2H), 3.74 (d, J = 14.2 Hz,
2H), 3.70 (d, J = 14.2 Hz, 2H), 1.05 t, J = 7.1 Hz, 3H); 13C NMR (60 MHz, DMSO-d6) δ
165.0, 147.1, 141.1, 131.6, 123.4, 96.9, 63.0, 39.6, 13.3; HRMS (FAB) calcd for
C18H17N3O8 (M + H)+ 404.1094, found 404.1094. Anal. Calcd for C18H17N3O8: C, 53.60;
H, 4.25; N, 10.42. Found: C, 53.40; H, 4.51; N 10.31.
Ethyl 2-(4-cyanobenzyl)-2-nitro-3-(4-cyanophenyl)propanoate (3.4c)
This compound was prepared from 4-cyanobenzyl bromide in 82% yield by
using the same procedure as described for 3.4b. mp 138-139 OC; 1H NMR (250 MHz,
DMSO-d6) δ 7.83 (d, J = 8.3 Hz, 4H), 7.41(d, J = 8.3 Hz, 4H), 4.08 (q, J = 7.1 Hz, 2H),
3.76 (d, J = 14.2 Hz, 2H), 3.69 (d, J = 14.2 Hz, 2H), 1.03t, J = 7.1 Hz, 3H); 13C NMR (60
MHz, DMSO-d6) δ165.0, 139.0, 132.3, 131.2, 118.5, 110.7, 96.9, 62.9, 39.9, 13.3;
HRMS (FAB) calcd for C20H17N3O4 (M + H)+ 364.1297, found 364.1298. Anal. Calcd
for C20H17N3O4: C, 66.10.; H, 4.72; N, 11.56. Found: C, 65.93; H, 4.97; N 11.55.
Ethyl 2,2-bis(methylcarboxybenzyl)-2-nitroacetate (3.4d)
This compound was prepared from methyl 4-(bromomethyl)benzoate in 72%
yield by using the same procedure as described for 3.4b. mp 116-117 OC; 1H NMR (250
MHz, DMSO-d6) δ 8.01-7.97 (m, 4H), 7.26-7.21 (m, 4H), 4.14 (q, J = 7.2 Hz, 2H), 3.92
(s, 6H), 3.53 (s, 4H), 1.13 (t, J = 7.2 Hz, 3H); 13C NMR (60 MHz, DMSO-d6) δ 165.8,
165.2, 138.7, 130.6, 129.2, 129.0, 96.9, 62.8, 52.1, 39.9, 13.3; HRMS (FAB) calcd for
C22H23NO8 (M + H)+ 430.1502, found 430.1492. Anal. Calcd for C22H23NO8: C, 61.53;
H, 5.40; N, 3.26. Found: C, 61.66; H, 5.62; N 3.26.
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Bis(tert-butyl)-3-ethylcarboxy-3-nitroglutarate (3.4e)
This compound was prepared from tert-butyl bromoacetate in 79% yield by using
the same procedure as described for 3.4b. 1H NMR (250 MHz, CDCl3) δ 4.25 (q, J = 7.2
Hz, 2H), 3.42 (d, J = 16.8 Hz, 2H), 3.30 (d, J = 16.8 Hz, 2H), 1.42 (s, 18 H), 1.24 (t, J =
7.2 Hz, 3H);13C NMR (60 MHz, CDCl3) δ 167.4, 165.0, 90.0, 82.6, 63.5, 39.9, 28.1,
13.9; Anal. Calcd for C16H27NO8: C, 53.18; H, 7.53; N, 3.88. Found: C, 53.04; H, 7.33;
N 3.81.
Ethyl 2,2-bis(allyl)-2-nitroacetate (3.4f)
This compound was previously prepared by Pd-mediated approaches.3.42 In this
work 3.4f was prepared from allyl iodide by using the same procedure as described for
3.4a followed by flash chromatography (hexane-ether, 1:3) to provide 3.4f in 45 % yield.
1

H NMR (250 MHz, CDCl3) δ 5.68-5.57 (m, 2H), 5.24-5.17 (m, 4H), 4.27 (q, J = 7.2 Hz,

2H), 2.97-2.90 (m, 4H), 1.29 (t, J = 7.2 Hz, 3H); 13C NMR (60 MHz, CDCl3) δ 166.8,
129.5, 121.6, 95.0, 62.9, 38.2, 14.1;MS (FAB) calcd for C10H15NO4Na (M + Na)+ 236.1,
found 236.1. Anal. Calcd for C10H15NO4: C, 56.32; H, 7.09; N, 6.57. Found: C, 56.41;
H, 6.98; N 6.53.
Ethyl 2,2-bis(2-phenylsulfonyl ethyl)-2-nitroacetate (3.4g)
To a solution of ethyl nitroacetate (0.4g, 3.0 mmol) in acetonirile (5 mL) was
added DIEA (0.79 g, 6.15 mmol) and tetraethylammonium bromide (0.09 g, 0.3 mmol).
To this solution, phenyl vinylsulfone (1.03 g, 6.15 mmol) was added dropwise and the
solution was stirred at room temperature for 30 hrs. The acetonitrile was then removed in
vacuo and the residue was dissolved in ethyl acetate (25 mL). The resulting solution was
washed with 10% aqueous K2CO3 (2 x 10 mL), dried over anhydrous sodium sulfate,
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and the solvent was removed in vacuo to give 3.4g as a light yellow solid. Yield, 0.98 g
(70%). mp 88- 89 OC; 1H NMR (250 MHz, CDCl3) δ 7.92-7.59 (m, 10H), 4.25 (q, J =
7.1 Hz, 2H), 3.17-3.10 (m, 4H), 2.60-2.53 (m, 4H), 1.26 (t, J = 7.1 Hz, 3H); 13C NMR
(60 MHz, CDCl3) δ 164.3, 138.1, 134.2, 129.5, 127.8, 92.8, 63.6, 49.3, 26.6, 13.3;
HRMS (FAB) calcd for C20H23NO8S2 (M + H)+ 470.0977, found 470.0936. Anal. Calcd
for C20H23NO8S2: C, 51.16; H, 4.94; N, 2.98; S, 13.66. Found: C, 51.11; H, 5.07; N,
3.00; S, 13.51.
Bis(tert-butyl)-4-ethylcarboxy-4-nitropimelate (3.4h)
This compound was prepared from tert-butyl acrylate in 89% yield by using the
same procedure as described for 3.4g. 1H NMR (250 MHz, DMSO-d6) δ 4.24 (q, J = 7.1
Hz, 2H), 2.41-2.20 (m, 8H), 1.40 (s, 18H), 1.21 (t, J = 7.1 Hz, 3H); 13C NMR (60 MHz,
DMSO-d6) δ 170.3, 165.8, 94.5, 80.3, 62.9, 29.0, 28.3, 27.6, 13.5; HRMS (FAB) calcd
for C18H31NO8 (M + H)+ 390.2128, found 390.2118. Anal. Calcd for C18H31NO8: C,
55.51; H, 8.02; N, 3.60. Found: C, 55.31; H, 7.83; N, 3.87.
4-Ethylcarboxy-4-nitropimelonitrile (3.4i)
This compound was prepared from acrylonitrile in 87% yield by using the same
procedure as described for 3.4g. 1H NMR (250 MHz, DMSO-d6) δ 4.27 (q, J = 7.1 Hz,
2H), 2.70-2.54 (m, 8H), 1.24 (t, J = 7.1 Hz, 3H);

13

C NMR (60 MHz, DMSO-d6)

δ 164.7, 118.9, 93.2, 63.5, 28.5, 13.4, 11.7; HRMS (FAB) calcd for C10H13N3O4Na (M +
Na)+ 262.0804, found 262.0809. Anal. Calcd for C10H13N3O4: C, 50.20; H, 5.48; N,
17.56. Found: C, 50.07; H, 5.36; N, 17.61.
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Figure 3.8 Synthesis of Fmoc-protected ααAAs.

3.4.2

Ethyl 2,2-Dibenzylglycine Ester (3.5a)
To a solution of nitro ester 3.4a (1.0 g, 3.19 mmol) in glacial AcOH (15 mL) at

15 OC, Zn dust (0.63 g, 9.57 mmol) was added in several portions over 1 h. The
resulting mixture was allowed to warm to room temperature and vigorously stirred for
24 h. The solids were filtered off, washed with 1.0 M HCl (2 x 5 mL) and the combined
filtrates were concentrated to an oil. This oil was dissolved in a mixture of ethyl acetate
(10 mL) and aqueous 1 M NaOH (15 mL), and stirred for 24 h. The organic layer was
separated, dried (MgSO4), and evaporated in vacuo to provide amino ester 3.5a as a
white solid (0.73 g, 81% yield). mp 93-95 ºC; 1H NMR (250 MHz, DMSO-d6) δ 7.30-
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7.16 (m, 10H), 4.0 (q, J = 7.2 Hz, 2H), 3.18 (d, J = 12.9 Hz, 2H), 2.77 (d, J = 12.9 Hz,
2H), 1.43 (s, 2H), 1.16 (t, J = 7.2 Hz, 3H),

13

C NMR (60 MHz, DMSO-d6) δ 174.8,

136.6, 130.0, 128.0, 126.6, 62.6, 60.3, 45.9, 14.0; HRMS (FAB) calcd for C18H21NO2
(M + H)+ 284.1650, found 284.1637. Anal. Calcd for C18H21NO2: C, 76.29; H, 7.47; N,
4.94. Found: C, 76.37; H, 7.31; N, 4.83.
3.4.3

Ethyl 2,2-Bis(tert-butylcarboxylmethyl)glycine Ester (3.5e)
To a solution of 3.4e (1.3 g, 3.92 mmol) in absolute ethanol (10 mL), glacial acid

(1 mL) and a 50 % (w/w) slurry of Raney nickel in water (1.0 g) were added. The
reaction was hydrogenated over H2 gas (50 psi) for 24 hrs. The resulting solution was
filtered carefully over Celite and the Celite cake washed with EtOH (30 mL). The
solvent was removed in vacuo and the crude was dissolved in diethyl ether (30 mL).
After washed with saturated sodium carbonate (30 mL) and brine, the organic fraction
was dried over anhydrous sodium sulfate and rotary evaporated to yield 5e in 92% yield.
1

H NMR (250 MHz, CDCl3) δ 4.12 (q, J = 7.2 Hz, 2H), 2.67 (d, J = 15.5 Hz, 2H),

2.48(d, J = 15.5 Hz), 2.26 (s, 2H), 1.37 (s, 18H), 1.20 (t, J = 7.2 Hz, 3H); 13C NMR (60
MHz, CDCl3) δ 174.9, 169.7, 81.5, 61.5, 57.7, 45.0, 28.1, 14.2; Anal. Calcd for
C16H29NO6: C, 57.99; H, 8.82; N, 4.23. Found: C, 58.07; H, 8.86; N, 4.03.
3.4.4

Ethyl 2,2-Bis(tert-butylcarboxyethyl)glycine Ester (3.5h)
This compound was prepared from 3.4h in 92% yield by using the same

procedure as described for 3.5e. 1H NMR (250 MHz, DMSO-d6) δ 4.09 (q, J = 7.2 Hz,
2H), 2.34-1.64 (m, 8H), 1.81 (s, 2H), 1.38 (s, 18H), 1.18 (t, J = 7.2 Hz, 3H); 13C NMR
(60 MHz, DMSO-d6) δ 175.2, 172.0, 79.5, 60.4, 59.2, 34.2, 29.8, 27.6, 14.0; MS (FAB)
calcd for C18H33NO6 359.46 , found 359.35.
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3.4.5

Ethyl 2,2-Bis(tert-butylcarboxyethyl)-N-Hydroxyglycine Ester (3.6h)
To a solution of 3.4h (1.0 g, 2.57 mmol) in absolute ethanol (15 mL), 10 %

(w/w) palladium on carbon (0.1 g) was added carefully. The reaction was hydrogenated
over H2 gas (50 psi) for 24 hrs. The resulting solution was filtered carefully over Celite
and the Celite cake washed with EtOAc (30 mL). The organic filtrate was dried over
anhydrous sodium sulfate and rotary evaporated to yield 3.6h in 97% yield. 1H NMR
(250 MHz, DMSO-d6) δ 7.23 (s, 1H), 5.69 (s, 1H), 4.06 (q, J = 7.2 Hz, 2H), 2.17-2.13
(m, 4H), 1.74-1.70 (m, 4H), 1.37 (s, 18H), 1.17 (t, J = 7.2 Hz, 3H); 13C NMR (60 MHz,
DMSO-d6) δ173.6, 172.0, 79.5, 66.6, 29.1, 27.7, 26.3, 14.0; MS (FAB) calcd for
C18H33NO7 (M + H)+ 376.47, found 376.77.
3.4.6

2,2-Dibenzylglycine (3.1a)
A suspension of 3.5a (2.0 g, 7.1 mmol) in 2 M KOH (50 mL) and ethanol (25

mL) was refluxed under N2 for 24 h. The resulting mixture was concentrated to 20 mL
in vacuo and the mixture was acidified to pH 6.5 with concentrated HCl. The white
precipitate was filtered, washed with water (5 mL) and dried to provide the amino acid
3.1a (1.58 g, 6.2 mmol) in 88% yield (mp > 300 °C). 1H NMR (250 MHz, CD3OD) δ
7.27 (bs, 10H), 3.36 (d, J = 13.3 Hz, 2H), 2.85 (d, J = 13.3 Hz, 2H), 1.27 (s, 2H),
HRFAB-MS calcd exact mass [M + Na]+ 278.1157, obsd 278.1159; HRMS (FAB) calcd
for C16H17NO2Na (M + Na)+ 278.1157, found 278.1159. Anal. Calcd for C16H17NO2: C,
75.27; H, 6.71; N, 5.48. Found: C, 75.34; H, 6.64; N, 5.30.
3.4.7

2,2-Bis(tert-butylcarboxymethyl)glycine (3.1e)
To a solution of 3.5e (2.0 g, 6.03 mmol) in ethanol (20 mL) was added LiOH (0.4

g, 18.1 mmol) in water (10 mL). The reaction was stirred at 50 OC for 3 hrs followed by
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the same work-up procedure as described for 3.1a to provide the amino acid as a white
solid. Yield, 1.53 g (82%). 1H NMR (250 MHz, DMSO-d6) δ 2.78 (d, J = 17.2 Hz, 2H),
2.69 (d, J = 17.2 Hz), 1.37 (s, 18H);

13

C NMR (125 MHz, DMSO-d6) δ 175.8, 173.7,

85.7, 62.7, 43.3, 30.5; HRMS (FAB) calcd for C14H25NO6 (M + H)+ 304.1760, obsd
304.1760.
3.4.8

Nα-(9-Fluorenylmethoxycarbonyl)-2,2-Dibenzylglycine (3.7a)
TMSCl (0.85 g, 7.84 mmol) was added to a suspension of amino acid 3.1a (1.0

g, 3.92 mmol) in dry CH2Cl2 (20 mL) and refluxed under N2 for 8 h. The mixture was
cooled to 0 °C, and DIEA (1.01 g, 7.84 mmol) and Fmoc-Cl (1.01 g, 3.92 mmol) were
added. The reaction was allowed to warm to 25 °C and stirred for 30 h. The resulting
mixture was concentrated in vacuo to provide a yellow solid which was dissolved in
aqueous 10% NaHCO3. This solution was washed with Et2O (3 x 15 mL), the aqueous
layer was acidified to pH 2.0 with HCl, and extracted with EtOAc (3 x 35 mL). The
combined EtOAc layers were dried (MgSO4) and concentrated in vacuo to provide a
light yellow solid. The crude product was purified by crystallization from Et2O-hexanes
to give the protected ααAA 3.7a as a white solid (1.5 g, 80% yield). mp 184-185 °C; 1H
NMR (250 MHz, CDCl3) δ 7.81-7.10 (m, 18H), 5.50 (s, 1H), 4.49 (d, J = 7.0 Hz, 2H),
4.29 (t, J = 7.0 Hz, 1H), 3.90 (d, J = 13.6 Hz, 2H), 3.26d, J = 13.6 Hz, 2H); 13C NMR (60
MHz, CDCl3) δ 177.2, 155.0, 144.2, 141.7, 136.1, 130.1, 128.8, 128.1, 127.5, 125.6,
120.4, 67.1, 66.9, 47.7, 41.5; HRMS (FAB) calcd for C31H27NO4 (M + H)+ 478.2018,
found 478.1996. Anal. Calcd for C31H27NO4: C, 77.96; H, 5.70; N, 2.93. Found: C,
78.15; H, 5.85; N 2.99.
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3.4.9

Nα-(9-Fluorenylmethyloxycarbonyl)-2,2-Bis(tert-butylcarboxymethyl)glycine
(3.7e)
This compound was prepared from 3.1e in 71% yield by using the same

procedure as described for 3.7a. 1H NMR (250 MHz, CDCl3) δ7.76-7.24 (m, 8H), 6.33
(s, 1H), 4.32 (d, J = 7.0 Hz, 2H), 4.20 (t, J = 7.0 Hz, 1H), 3.37 (d, J = 15.1 Hz, 2H), 2.85
(d, J = 15.1 Hz, 2H), 1.38 (s, 18H);

13

C NMR (60 MHz, DMSO-d6) δ 171.9, 168.4,

153.9, 143.7, 140.7, 127.6, 127.0, 125.1, 120.1, 80.1, 65.6, 57.9, 46.5, 39.7, 27.6; Anal.
Calcd for C29H35NO8: C, 66.27; H, 6.71; N, 2.66. Found: C, 66.48; H, 6.87; N 2.56.
3.5
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CHAPTER 4
SYNTHESIS OF NOVEL β-STRAND MIMICS AND ITS APPLICATION TO
THE DEVELOPMENT OF INHIBITORS OF AMYLOID FIBRIL*
4.1

Introduction
Development of small molecules that mimic the structures of bioactive peptides

has gained increased interest in the past twenty years.4.1-4.4 The de novo design and
synthesis of artificial peptides with well-defined secondary structures facilitates protein
folding studies and offers the promises of creating pharmacologically useful analogues
of bioactive peptides. One of the commonly studied molecules is the antimicrobial
peptides that adopt helical structures induced by Cα,α-disubstituted amino acids
(ααAA).4.3,

4.5

A number of ααAAs including α-aminoisobutyric acid (Aib) and 4-

aminopiperidine-4-carboxylic acid (Api) have been employed in the antimicrobial
peptide design. Unlike helix mimics, β-strand mimics with the tendency to form
interstrand hydrogen bonds have not been well investigated. β-sheets are important
structural elements in proteins and are in involved in various biological processes such
as protein polymerization, substrate recognition, and electron transfer.4.6-4.7
It is believed that the oligomerization of monomeric β-amyloid peptide (Aβ) into
insoluble fibrils plays a key role in the progression of Alzheimer’s disease (AD).4.8-4.11

*Reprinted in part with permission from Organic Letters, 2002, Volume 4, pages 237240; Fu, Y. and Hammer, R. P., Efficient Acylation of the N-terminus of Highly
Hindered Cα,α-Disubstituted Amino Acids via Amino Acid Symmetrical Anhydrides
Copyright 2002 American Chemical Society.
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Alzheimer’s disease is associated with gradually formed proteinaceous deposits, called
amyloid plaques, which may displace and kill brain cells by triggering inflammation and
by damaging the cell’s interiors.4.10-4.11 Deposition of insoluble amyloid fibrils as
amyloid plaques in the neuropil is the key step in the pathogenesis of AD.4.10-4.13 The
principle component of the amyloid fibril is β-amyloid peptide (Aβ), a hydrophobic
peptide which exists either as anti-parallel or parallel β-sheet, or the mixture.4.14-4.15
Figure 4.1 displays the parallel β-sheet segment in amyloid fibril. Lomakin et al.

O K H
N
H

O

O V H

N
H L H

O

O K H
N
H

H
N

H
N

O

N
H L H

H
N

O

F H

N
H F H

O

VH

O

H
N

O

N
HF H

H
N

N
HA H

O

F H
O

O E H

H
N

O

O

VH

N
HD H

O

O E H

N
HA H

H
N

H
N

O

N
HD H

H
N

O

VH

H
N

O

Figure 4.1 Section of parallel β-sheet structure in amyloid fibril.

reported two main pathways for amyloid fibril initiation and growth (Figure 4.2).4.16
When Aβ is above a critical concentration (~ 10-30 µM), it will aggregate to form
micelle (M) which can rearrange into protofibril (P). The further growth and aggregation
of protofibril eventually lead to the formation of fibril (F). At lower concentration of Aβ,
the presence of an alternative element is required to initiate the accumulation and
aggregation of Aβ to form a protofibrillar-like species P’. The gradual growth of P’ can
lead to fibrillar structure F’.
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Figure 4.2 Aβ initiation and growth. (A) Concentration of Aβ is above the critical
concentration; (B) Concentration of Aβ is below the critical concentration.

In practice, the surface of all species Αβ, M, P/P’ and F/F’ may be very similar,
with at least one edge open allowing hydrogen-bond formation. We hypothesize that in
the presence of “blocker” peptides, which could interact with F/F’, P/P’, M, and the
single Aβ, the growth of Aβ to fibril may become reversible and the dissolution of Aβ
from F (or its intermediates) may be promoted. The design of amyloidogenesis inhibitors
is based on novel β-strand mimics, in which natural L-amino acids and Cα,αdisubstituted amino acids with large side chains are at alternating sequence positions
(Figure 4.3). It has been reported that ααAAs with bulky side chains favor extended
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Figure 4.3 Blocker peptide design.

conformation.4.17-4.20 For example, crystal structure study revealed that Cα,αdibenzylglycine (Dbzg) exclusively adopted extended C5 conformation (Figure 4.4) in
solid state.4.21-4.22 Incorporation of the sterically hindered ααAAs with C5 structure
preference is likely to promote extended peptide backbone conformation. Alternating
natural L-amino acids and ααAAs in the peptide chain allows hydrogen bonding on one
edge, while blocking hydrogen bonding on the opposite edge. To test our hypothesis, we
have proposed both parallel and anti-parallel blocker peptides of amyloid fibril based on
the hydrophobic core Aβ16-20 (Figure 4.5). In the blocker peptides, the natural amino
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Figure 4.4 The extended C5 conformation of Dbzg.
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acids are the same as the amino acids in Aβ16-20, while the ααAAs are the achiral
analogues of the natural amino acids in the hydrophobic core. The conformationally
constrained blocker peptides are likely to adopt extended structures and interact with the
hydrophobic core on opening edge of amyloid fibril based on “like likes like” residue
relationship.
Preparation of the designed β-srand mimics is synthetically challenging, as the
sterically hindered ααAAs inhibit efficient amide bond formation. The ααAAs with
short side chains such as α-aminoisobutyric acid (Aib), Cα,α-diethylglycine (Deg), and
Cα,α-dipropylglycine (Dpg) have been incorporated into peptides by a variety of
methods, including standard carbodiimide protocols, urethane-protected N-carboxy
anhydrides, activated oxazolones, amino acid fluorides, and HOAt-based uranium (e.g.,
HATU) and phosphonium salts (e.g., PyAOP).4.19,

4.23-4.31

Incorporation of more

demanding ααAAs such as Cα,α-dibenzylglycine (Dbzg), Cα,α-diisobutylglycine (Dibg),
or 2,2,6,6-tetramethylpiperdine-1-oxyl-4-carboxylic acid (TOAC) into peptides is more
problematic. For example, incorporation of Dbzg or TOAC onto a growing peptide chain
was readily accomplished by activated ααAA oxazolones or traditional HBTU coupling
reagent.4.32-4.33 In contrast, acylation of the N-terminus of Dbzg or TOAC with
DCC/HOBt, mixed anhydride, or HATU only gave low to moderate yields.4.32-4.34 Thus
the difficulties in incorporating sterically hindered ααAAs into internal position of
peptide chains mainly stem from the inefficient acylation of the ααAA N-termini.
Several other groups have previously found that secondary amino acids acylate
poorly in situ reagents (DCC/HOBt; HOBt/HOAt-derived uranium or phosphonium
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salts), but more readily react with symmetrical anhydrides in nonpolar solvents such as
dichloromethane.4.35-4.36 The previous results offer a promise for developing novel
strategy to acylate constrained ααAAs. In this work, preformed symmetrical anhydride
(Figure 4.6) is employed to acylate N-terminus of sterically hindered ααAAs such as
Dbzg and Dibg. Using the symmetrical anhydride method, a potential inhibitor of
amyloid fibril is prepared. Also preliminary biological study is carried out to measure
the inhibitor’s property against amyloid aggregation.
4.2

Results and Discussion

4.2.1

Acylation of N-terminus of Sterically Hindered ααAAs
As part of our ongoing program aimed at conformationally restricted peptides

containing ααAAs at alternating sequence positions, peptides DBZG-1 and DIBG-1
were assembled using Fmoc-solid-phase synthesis. We have found that PyAOP (also see
chapter 1 and Chapter 2) is a powerful reagent for incorporation of less hindered ααAAs
such as Dpg into peptide internal position at elevated temperature (see Chapter 2). In the
DBZG-1: H-Lys-Dbzg-Ala-Dpg-Glu-CONH2
DIBG-1: H-Lys-Dibg-Ala-CONH2

97

Table 4.1 Coupling of Fmoc-Lys(Boc)-OH onto (A) H-Dbzg-Ala-Dpg-Glu(OtBu)-resin
and (B) H-Dibg-Ala-resin.a

Entry Coupling
method

a
b

Base

Solvent

Time
(hr)

Temp
(oC)

Coupling
yield (%)b
A
B

1

PyAOP

DIEA

DMF

8

50

<10

-

2

PyAOP

DIEA

DCE-DMF
(1:1)

8

50

20

22

3

PyAOP-HOAt

DIEA

DCE-DMF
(1:1)

8

25

25

26

4

PyAOP-HOAt

DIEA

DCE-DMF
(1:1)

8

50

-

35

5

HATU

DIEA

DMF

8

25

18

32

6

HATU

DIEA

DCE-DMF
(1:1)

8

50

-

46

7

Fmoc-Lys(Boc)-F DIEA

DCE-DMF
(1:1)

8

50

26

28

8

Fmoc-Lys(Boc)-F DIEA

DCE-DMF
(9:1)

8

50

46

50

9

Symm. anhydride

No base

CH2Cl2

8

25

-

62

10

Symm. anhydride

No base

DCE-DMF
(9:1)

3

50

95

91

11

Symm. anhydride

No base

DCE-DMF
(1:1)

3

50

81

73

12

Symm. anhydride

No base

DMF

3

50

52

34

13

BOP-Cl

No base

CH2Cl2

8

25

49

53

14

BOP-Cl

No base

DCE-DMF
(9:1)

8

50

88

-

Both peptides were synthesized on Fmoc-PAL-PEG-PS resin.
The coupling yield was determined by UV analysis of the Fmoc-deprotection.4.37
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synthesis of peptide DBZG-1 and DIBG-1, we have found that coupling of Fmoc-DbzgOH and Fmoc-Dibg-OH onto the N-terminus of Alanine using PyAOP at elevated
temperature was relatively efficient. However, once Dbzg or Dibg was at the N-terminus
of the peptide, the following acylation of the ααAAs became very difficult (Table 4.1,
entries 1-8). In our work, coupling of Fmoc-Lys(Boc0-OH onto the N-terminus of Dbzg
or Dibg using PyAOP in DMF was ineffective (Talbe 4.1, entry 1). When the coupling
was performed in a low polarity solvent mixture (DCE-DMF, 1:1), improved but still
low yields were obtained (Table 4.1, entries 2-4). The attempted acylation of N-terminus
of Dbzg of Dibg using HATU also gave a low yield at room temperature, while the
acylation of Dibg at 50 ºC resulted in a moderate yield (Table 4.1, entries 5-6). When an
amino acid fluoride protocol was utilized,4.38 the acylation in DCE-DMF (1:1) gave low
yields for both Dbzg and Dibg. Interestingly, when the acylations were carried out in a
less polar solvent mixture of DCE-DMF (9:1), improved yields were obtained (Table
4.1, entries 7-8).
Previous studies showed symmetrical anhydrides could readily acylate Nsubstituted secondary amino acids in a nonpolar solvent such as CH2Cl2.4.35-4.36 In our
hands we found that the symmetrical anhydride of Fmoc-Lys(Boc)-OH in CH2Cl2 in the
absence of base gave an improved yield (62%) in the acylation of the Dibg-resin at room
temperature (Table 4.1, entry 9). On the basis of our previous work, we found that the
coupling could be improved at elevated temperatures. Thus, the symmetrical anhydride
we prepared in CH2Cl2 was concentrated and redissolved in the higher boiling DCEDMF mixture. Now a 3 h coupling in DCE-DMF (9:1) at 50 ºC gave an acylating yield
of 95% for the Dbzg-resin and 91% for the Dibg-resin (Table 4.1, entry 10). It was also
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observed that activated mixed anhydride formed by BOP-Cl4.39 and Lys gave very good
coupling yield at elevated temperature (Table 4.1, entry 14). It is not as yet understood
why the symmetrical anhydride method is so much more efficient at acylating the
sterically hindered Dbzg and Dibg residues than methods based on uranium,
phosphonium salts, or amino acid fluorides. One possibility is that the symmetrical
anhydride may possess an enhanced reactivity in the aprotic nonpolar solvent for which
anchimeric assistance from H-bonding is more pronounced (Figure 4.7). The results bear

R
R

O
R

H N
R'

O

H

R
O

R

O
H N
R'

O

H

O

O
R

O
NH

O
H

R'

Figure 4.7 Anchimeric assistance provided by the H-bond donation.

this out in that coupling of the symmetrical anhydride in non-polar solvent gives higher
yields than the couplings in more polar solvents (Table 4.1, entries 11-12). When the
reaction of the symmetrical anhydride was performed in the more H-bond accepting
solvent mixture of DCE–DMF (1:1) or in pure DMF, the coupling efficiency
systematically decreased. The peptide DBZG-1 and DIBG-1 were prepared using the
optimized coupling conditions and cleaved from the resin by 88% TFA and analyzed by
reversed-phase HPLC (Figure 4.8, Figure 4.9).
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(A)

H-Lys-Dbzg-Ala-Dpg-Glu-CONH2—

(B)
379.1 CCA matrix

747.1 [M + Na]+

Figure 4.8 HPLC and MS profiles of DBZG-1. (A) HPLC profile of crude peptide
DBZG-1; (B) MALDI-MS spectrum of the main peak on HPLC. For MS of DBZG-1,
m/z calcd. [M + Na]+ 746.9, obsd. 747.1.
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(A)
H-Lys-Dibg-Ala-CONH2

(B)

408.4 [M + Na]+
386.4 [M + H]+

Figure 4.9 HPLC and MS profiles of DIBG-1. (A) HPLC profile of crude peptide
DIBG-1; (B) MALDI-MS spectrum of the main peak on HPLC. For MS of DIBG-1, m/z
calcd. [M + Na]+ 408.5, obsd. 408.4.
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4.2.2

Synthesis of Amyloid Blocker Peptide
The proposed amyloid block peptides are analogous of hydrophobic core Aβ16-20,

which contains ααAAs and L-amino acids at alternating sequence positions (Figure 4.5).
In the sequence of parallel blocker peptide AMY-1, Phe, Val, or Lys is at either the C- or
N-terminus of Dbzg and Dibg, which could make efficient amide bond formation at
AMY-1: H-Lys-Dibg-Val-Dbzg-Phe-Dpg-(Lys)6-CONH2
both termini of the ααAAs difficult. To optimize the yield of the peptide, three
activation methods were utilized during the peptide assembly (Figure 4.10). The first six
lysine residues were coupled to PAL-PEG-PS resin under PyAOP/DIEA/DMF coupling
conditions on peptide synthesizer. The rest of amino acid residues were incorporated
manually into the sequence. Dpg and Phe were incorporated into peptide using
PyAOP/DIEA in DCE-DMF (1:1). Coupling of Fmoc-Dbzg-OH onto Phe was also
performed using PyAOP at 50 ºC in which an 89% yield was obtained after 8 hours. In
contrast, the coupling of Fmoc-Dibg-OH onto Val using PyAOP/HOAt at 50 ºC only
gave a 58% yield after 12 hours. When the coupling of Fmoc-Dibg-OH onto Val was
performed under HATU/HOAt conditions, an improved yield (81%) was obtained.
As we experienced before, once the Dbzg or Dibg was at the N-terminus of the
peptide, the following acylation of the ααAAs was very difficult (Figure 4.11).
Monitoring of the coupling of Fmoc-Val or Fmoc-Lys to the highly hindered N-terminus
of Dbzg or Dibg, respectively, using PyAOP/HOAt or amino acid fluorides showed that
only low to moderate yields were obtained after prolonged reaction time. Attempted
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H3CO
FmocHN

O
O

(CH2)4

H3CO
Fmoc removal

N PEG PS
H

PyAOP/ Fmoc-Lys(Boc) -OH
DIEA

Fmoc removal

PyAOP/Fmoc-Dpg-OH
DIEA

Fmoc removal

PyAOP/Fmoc-Phe-OH
DIEA

Fmoc removal

PyAOP/Fmoc-Dbzg-OH
DIEA

Fmoc removal

(Fmoc-Val)2O

Fmoc removal

HATU/Fmoc-Dibg-OH
DIEA

Fmoc removal

(Fmoc-Lys(Boc))2O

Fmoc-Lys(Boc)-Dibg-Val-Dbzg-Phe-Dpg-(Lys(Boc))6-HN
Fmoc removal

TFA solution

H-Lys-Dibg-Val-Dbzg-Phe-Dpg-(Lys)6-NH2

Figure 4.10 Assembly of potential amyloid assembly inhibitor AMY-1.

104

(A)
Yield of Fmoc-Val-Dbzg-Phe-Dpg-(Lys(Boc))6 -PAL-PEG-PS (%)

100
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80

(Fmoc-Val)2 O
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Fmoc-Val-F
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PyAOP/HOAt
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20
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0
0
(B)

3

6
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Yield of Fmoc-Lys(Boc)-Dibg-Val-Dbzg-Phe-Dpg-(Lys(Boc))6 PAL-PEG-PS (%)

100
90
80

(Fmoc-Lys(Boc))2 O

70
60

Fmoc-Lys(Boc)-F

50

PyAOP/HOAt

40
30
20
10
0
0

3

6

t (h)

9

12

15

Figure 4.11 Monitoring the acylation of N-terminus of ααAAs. (A) Coupling of FmocVal-residue onto H-Dbzg-Phe-Dpg-(Lys(Boc))6-PAL-PEG-PS; (B) coupling of FmocLys(Boc)-residue onto H-Dibg-Val-Dbzg-Phe-Dpg-(Lys(Boc))6-PAL-PEG-PS.
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AMY-1

1731.4 [M + Na]+

Figure 4.12 HPLC and MS profiles of AMY-1. (A) HPLC profile of crude peptide
AMY-1; (B) MALDI-MS spectrum of the main peak on HPLC. For MS of AMY-1, m/z
calcd. [M + Na]+ 1731.3, obsd. 1731.4.
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Figure 4.13 Temperature-dependence of the CD spectra of AMY-1. Conditions: 250 µM
peptide in 10 mM phosphate buffer, pH 7.0.
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Coupling of Fmoc-Val-OH or Fmoc-Lys-OH to the N-terminus of Dbzg or Dibg under
HATU/HOAt conditions also gave low yields (32%, 35%) after 15 hours. In contrast, the
acylation using readily available Fmoc amino acid symmetrical anhydrides in low
polarity solvent without base resulted in excellent coupling yields. The deblocked
peptide was obtained in high quality and good yield as verified by HPLC and by
MALDI-MS (Figure 4.12).
The conformational preference of the β-strand mimic in aqueous solution is an
important property of the designed inhibitor, since polymerization could turn the
inhibitor itself into problematic aggregates. If the β-strand mimic aggregates, it is likely
to interact with another strand to form the β-sheet structure. The conformational
behavior of AMY-1 was studied by circular dichroism spectroscopy in phosphate buffer
(Figure 4.13). There is a positive band at 200 nm and two negative bands at 190 and 230
nm, respectively in the CD spectra. The overall shape of the CD spectra indicated the
content of β-turn secondary structure in aqueous solution,4.40-4.42 like peptide DPG-2
described in Chapter 2. Upon heating, the band at 190 nm became slightly weaker, and
the bands at 200 nm and 230 nm were almost unchanged, indicating a stable content of
the secondary structure.
4.2.3

Preliminary Biological Study of Inhibitor AMY-1
The design of the amyloid inhibitor is based on the central hydrophobic core

Aβ16-20, which is an essential core for Aβ fibrillogenesis.4.43-4.44 The blocker peptide
which contains L-amino acids and ααAAs at alternating sequence positions is likely to
adopt extended conformation and interact with the hydrophobic core on fibril opening
strand based on “like likes like” residue relationship. The presence of ααAAs at
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alternation sequence positions allows hydrogen bonding on one side of the β-strand
mimics, while blocking further addition from the opposite side thus preventing the
growth the amyloid aggregates. The incorporation of oligolysine at the C-terminus could
also prevent elongation of the amyloid β-structures4.45 and increase the inhibitor’s
solubility in aqueous solution.
The inhibitor’s efficacy was analyzed by Jed Aucoin in Dr. McCarley’s group. In
the study with atomic force microscopy (AFM), a mixture of AMY-1 to Aβ10-35 at a ratio
9:1 was compared to a control of only Aβ10−35. The control sample that contained 50 µM
Aβ10-35 in 15 mM phosphate buffer and 150 mM NaCl at pH 7.3 was incubated at 37 ºC
for 14 hours. Figure 4.13 shows the incubated control sample adsorbed onto mica.4.46
There were a number of fibril-like species with varying length between 560-700 nm and
a range of aggregate height of 2-28 nm. When AMY-1 was co-incubated with Aβ10-35 at
a ratio of 9:1 under the same conditions as the control, the fibril formation was not
present in the sample (Figure 4.13).4.46 Instead only a few spherical aggregates with 5070 nm width were obtained.
In another experiment, the inhibitor’s efficacy was analyzed by measurement of
samples consisting of AMY-1 and Aβ10-35 at other ratios. The control sample that
contained 300 µM Aβ10-35 in 116 mM NaCl at pH 7.5 was incubated at room
temperature for 9 days. It displayed a number of large aggregates with 1.5 µm in width
and 143 nm in height (Figure 4.14).4.46 In contrast, significant differences in aggregation
were observed in the samples containing AMY-1 and Aβ10-35 at 3:1 and 1:1 ratio
respectively. The 3:1 ratio sample contained a number of particles with about 300 nm in
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(A)

(B)

Figure 4.14 Effects of AMY-1 on aggregation of Aβ10-35 at 9:1 ratio at 37 ºC. (A)
Aβ10−35 (50 µM) was incubated in PBS (pH 7.3) and 150 mM NaCl for 14 h at 37 ºC. (B)
AMY-1 (450 µM) and Aβ10−35 (50 µM) were incubated under the same condition as
above.4.46
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(A)

(B)

(C)

Figure 4.15 Effects of AMY-1 on aggregation of Aβ10-35 at 3:1 and 1:1 ratio at 25 ºC.
(A) Aβ10−35 (300 µM) was incubated in 18 mM PBS (pH 7.5) and 116 mM NaCl for 9
days at 25 ºC; (B) AMY-1 (300 µM) and Aβ10−35 (300 µM) were incubated under the
same condition as above; (C) AMY-1 (900 µM) and Aβ10−35 (300 µM) were incubated
under the same condition as above.4.46

111

nm in width and 50 nm in height; the 1:1 ratio samples contained some small particles
with about 190 nm in width and 15 nm in height.
The preliminary study indicates that AMY-1 can effectively minimize the
aggregation of amyliodgenic Aβ10-35. Since the inhibitor and Aβ10-35 were mixed together
at the beginning of the incubation, it is likely that the blocker peptide attached to the
target site on monomeric amyloid peptide and/or growing amyloid species thus blocked
the further aggregation. However, we cannot rule out the possible competing pathway in
which the blocker peptide interacted with formed fibrils and promoted amyloid fibril
dissolution. The inhibitor’s property of dissociating fibrils can be analyzed by adding
AMY-1 to pre-incubated Aβ solution under optimized conditions.
4.3

Conclusions
Polymerization of amyloid β-peptides is a major feature in the pathological

process of Alzheimer’s disease. It is believed that hydrophobicity facilitates monomeric
Aβ interaction and thereby promotes amyloid fibril formation. The design of inhibitor
AMY-1 is based on the central hydrophobic core Aβ16-20. The characteristic feature of
the inhibitor is that it contains natural L-amino acids and constrained ααAAs at
alternating sequence positions.
AMY-1 was successfully assembled using solid-phase peptide synthesis, where
amino acid symmetrical anhydride protocol was utilized to efficiently acylate the Nterminus of highly hindered ααAAs. The preliminary aggregation study shows
impressive inhibitory activity of AMY-1. The application of AMY-1 and its analogs to
anti-aggregation study offers the promise of understanding the inhibition mechanism of
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anti-fibrillogenesis with β-strand mimics and may facilitate the development of novel
inhibitors which prevent amyloidogenesis in vivo in Alzheimer’s disease.
4.4

Experimental

4.4.1

Peptide Synthesis and Purification
Peptides DBZG-1 and DIBG-1 were manually synthesized on Fmoc-PAL-PEG-

PS resin. All coupling before acylation of Dbzg or Dibg were efficiently carried out
using PyAOP in DCE-DMF (1:1). Conditions: PyAOP, 4 equiv; DIEA, 8equiv; Fmoc
amino acids, 4 equiv (0.3M). Deblock, piperidine: DBU: DMF (5:2:93). Coupling of
Fmoc-Lys(Boc)-OH onto resin-bounded peptide was performed on 0.1 mmol scale resin
under different conditions. (i) Coupling using PyAOP and DIEA was carried out under
the same conditions as described above. Yield, 20% for DBZG-1 and 22% for DIBG-1.
(ii) Coupling of Fmoc-Lys(Boc)-OH (0.4 mmol, 4 equiv) was performed using PyAOP
(0.4 mmol, 4 equiv), HOAt (0.4 mmol, 4 equiv), and DIEA (0.8 mmol, 8 equiv) in DCEDMF (1:1) at room temperature. Yield, 25% for DBZG-1 and 26% for DIBG-1. (iii) The
acylation of N-terminal Dbzg and Dibg with Fmoc-Lys(Boc)-OH (0.2 mmol, 4 equiv)
using HATU (0.2 mmol, 4 equiv) and DIEA (0.4 mmol, 8 equiv) and DIEA (0.4 mmol,
8 equiv) in DMF at room temperature gave an 18% for DBZG-1 and 32% for DIBG-1.
(iv) The acylation using Fmoc-Lys(Boc)-F (0.2 mmol, 4 equiv), DIEA (0.2 mmol, 4
equiv) in DCE-DMF (9:1) at 50 ºC gave 46% yield for DBZG-1 and 50% yield for
DIBG-1. (v) Symmetrical anhydride was prepared by treatment of 2 equiv of FmocLys(Boc)-OH with 1 equiv of DCC in CH2Cl2 at room temperature or 2h and the
precipitated DCU was removed by filtration. The symmetrical anhydride coupling
method was performed by adding preformed (Fmoc(Boc))2O (0.3 mmol, 3 equiv) to the
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resin-bound peptide in DCE-DMF (9:1) in the absence of base. The reaction was carried
out at 50 ºC to give a 95% coupling yield for DBZG-1 and 91% yield for DIBG-1. (vi)
The mixed anhydride was prepared by treatment of 1 equiv of Fmoc-Lys(Boc)-OH with
1 equiv of BOP-Cl with the presence of 1 equiv of DIEA in CH2Cl2 at 0 ºC for 1h. The
concentrated mixed anhydride was taken up in proper solvent for coupling. The coupling
of the mixed anhydride (0.3 mmol, 3 equiv) to N-terminal Dbzg and Dibg in DCE-DMF
(9:1) at 50 ºC gave 88% yield for DBZG-1.
For the synthesis of AMY-1, the first six Lys residues were coupled to PALPEG-PS resin under PyAOP/DIEA/DMF coupling conditions on a Perseptive
Biosystems Peptide Synthesizer 9050. The rest of amino acid residues were incorporated
manually into the sequence. Dpg, Phe, and Dbzg were incorporated into sequence using
PyAOP/DIEA in DCE-DMF (1:1) under the same conditions for DBZG-1; Val residue
was coupled to N-terminus of Dbzg via amino symmetrical method under the same
conditions for DBZG-1; Dibg was coupled to Val using HATU (4 equiv), HOAt (4
equiv), DIEA (8 equiv), and Fmoc-Dibg-OH (4 equiv, 0.3M) in DCE-DMF (1:1) at 50
ºC; Lys residue was coupled to Dibg via symmetrical anhydride at 50 ºC.
After the peptide synthesis, the resin was treated with standard cleavage solution
(trifluoroacetic acid : triisopropylsilane : water: phenol, 8.8 : 0.2 : 0.5 : 0.5) at room
temperature for 2h to cleave the peptide from the solid support. After filtration, the
filtrate was diluted with cold 40% acetic acid solution, washed with cold diethyl ether (5
x 40 mL), and lyophilized to yield to crude peptides.
The crude peptides were purified by reverse phase HPLC using Waters Deltapak
C4 column (15 µm, 300 A, 25 x 100mm). The flow rate was 1 mL/Min for analytical
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HPLC and 10 mL/min for preparative HPLC. For all peptides, solvent A was 0.05%
TFA in water, solvent B was 0.05% TFA in acetonitrile. The identity and purity of the
peptides was confirmed by quantitative amino acid analysis and matrix-assisted laser
desorption/ionization mass spectrometry. For peptide DBZG-1, the purification was
carried out using a linear gradient from 10-60% B over 50 minutes, tR = 42.5 min,
overall yield 68%; MALDI [M + Na]+ m/z calcd. 746.9, obsd. 747.1. For peptide DIBG1, the purification was performed with a linear gradient from 10-50% B over 40 minutes,
tR = 10.1 min, overall yield 81%; MALDI [M + Na]+ m/z calcd. 408.5, obsd. 408.4.
Purification of AMY-1 was carried out using a linear gradient form 10-70% B over 60
minutes, tR = 42.9 min, overall yield 61%. MALDI [M + Na]+ m/z calcd. 1731.3, obsd.
1731.4.
4.4.2

Circular Dichroism
Circular dichroism measurements were performed on a (+)-camphor sulfonic

acid calibrated Aviv 60DS spectrophotometer. The samples were prepared as stock
solutions in buffer and diluted to the desired concentration in proper solution for
measurements. The CD measurements were recorded over a 250-180 nm range using a
quartz cell of 1 mm path length, 1 nm bandwidth, 20 nm/min scan speed, and a time
constant of 0.5 s. Molar ellipticity was calculated using the formula [θ] =
[θ]obs(MRW/10cd), where [θ]obs is the mean residue molecular weight of the peptide
(molecular weight divided by the number of peptide bonds), c is the concentration of the
sample in mg/mL, and d is the optical path length of the cell in cm. All spectra were
corrected for buffer (or solvent) contributions and presented in unit of molar ellipticity.
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4.4.3

Atomic Force Microscopy
The stock solution, controls, and samples created from the stock were prepared

for AFM analysis on the same day. The sample was placed onto a magnetic puck and
placed on top of the piezoelectric scan tube within the AFM instrument. Scans up to 125
µm2 can be captured with the vendor’s (Digital Instrument) software. After capturing the
image, a flatten procedure was performed and a top view allows the size of the
aggregates to be determined. The heights of these aggregates were determined using
bump analysis.
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CHAPTER 5
SUMMARY AND FUTURE STUDIES
5.1

Discussion
This dissertation has focused on design, synthesis, and structural analysis of short

peptides containing constrained Cα,α-disubstituted amino acid (ααAAs). Sterically
hindered ααAAs such as Cα,α-dibenzylglycine (Dbzg) and Cα,α-diisobutylglycine (Dibg)
have a strong tendency to adopt energetically favored extended structures.5.1-5.2
Incorporation of these sterically hindered ααAAs into alternating peptide sequence
position could induce extended conformations, which possess one blocked edge and one
opening edge for H-bonding formation. Sterically hindered ααAAs have not been
commonly used in de novo peptide design, mainly due to the difficulty in ααAA
preparation and peptide assembly. Development of new strategies to overcome the
problems associated with amino acid synthesis and coupling process is significant in
peptide research. In this study, the main application of the extended β-strand mimics is
the development of β-sheet blocker peptides, which could be utilized to prevent amyloid
fibril assembly. Synthesis of the amyloid blocker peptides and study of their
conformational and biological properties is crucial for potential therapeutical agent
development.
Chapter 2 of this dissertation describes the synthesis and conformational studies
of short peptides containing Cα,α-dipropylglycine (Dpg). Based on the fact the extended
C5 conformation is energetically favored over helical conformation in Dpg
derivatives,5.3-5.6 a number of pentapeptides containing Dpg at alternating sequence

121

position were designed. In these peptides, glutamic acid and/or lysine were placed at
each end of the sequence to probe the impact of side chain interaction on peptide
conformational preference. All peptides were assembled by solid-phase peptide
synthesis using Fmoc strategy. It was found that PyAOP was a powerful coupling
reagent for incorporation of Dpg into peptide internal positions at elevated temperature.
The experimental results also showed that acylation of N-terminus of Dpg was more
difficult than coupling at the C-terminus.5.7-5.8
Peptide conformational behavior was systematically studied by circular
dichroism (CD) and Nuclear Magnetic Resonance spectroscopy (NMR). The Dpg
peptide containing Lys and Glu at each end of the sequence exhibited stronger ellipticity
values than the peptides whose termini are both Glu or Lys. Side chain interaction was
also probed in pH dependence CD study where peptide DPG-2 exhibited systematically
decreased CD bands as the buffer solution goes from neutral to acidic. In both CD and
NMR studies, the Dpg peptides showed characteristic data indicating β-turn structures.
Based on NOE measurement, the solution structure of Dpg peptide was generalized and
energy minimized. It contained two consecutive β-turns whose H-bonds are stabilized by
side chain interaction between lysine and glutamic acid. It has been reported that high
alkyl analogues of Aib, such as Dpg, can accommodate either fully extended or helical
conformation, depending on peptide sequence, length, and environment.5.9 In our peptide
design, the Dpg residues might be in a “helix-friendly” context, so the Dpg residues
could comfortably fit into the helical (turn) conformation. To induce extended backbone
structure, Dpg needs to be incorporated into peptides whose residues have a strong
tendency to adopt extended conformation (Table 5.1). Cα,α-dibenzylglycine (Dbzg) is
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Table 5.1 Proposed β-strand mimics containing ααAAs.
Peptide

Sequence

DPG-6

Ac-Glu

Dpg

Val

Dpg

Lys-NH2

DPG-7

Ac-Glu

Dpg

Val

Dpg

Glu-NH2

DPG-8

Ac-Lys

Dpg

Val

Dpg

Lys-NH2

DBZG-2

Ac-Glu

Dbzg

Val

Dpg

Lys-NH2

DBZG-3

Ac-Lys

Dbzg

Val

Dpg

Glu-NH2

DBZG-4

Ac-Glu

Dbzg

Tyr

Dbzg

Lys-NH2

DBZG-5

Ac-Glu

Dbzg

Val

Dbzg

Lys-NH2

known for it overwhelming property to induce C5 conformation in solid state,5.1-5.2 while
valine has been found in a number of extended peptides.5.9 Incorporation of Val and/or
Dbzg into peptide sequence will provide interesting β-strand mimic samples for
conformational studies.
Chapter 3 describes the synthesis of sterically hindered ααAAs via ethyl
nitroacetate. Nitroacetate is a useful synthon for preparation of a number of important
organic compounds.5.10-5.11 Nitroacetates possess a high reactive α-carbon which can be
readily dialkylated under base-catalyzed mild conditions. It was observed that
nucleophilic addition to Cα-deprotonated nitroacetate was greatly enhanced with the
presence of a catalytic amount of tetraammonium alkyl halide. The high yields for these
dialkylation reactions made this a very useful synthetic route upon which orthogonally
protected ααAAs were obtained. This method has been shown to be successful for the
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synthesis of highly sterically hindered Fmoc-Dbzg-OH, as well as the synthesis of
chemically sensitive ααAAs, such as Nα- and side chain-protected tetrafunctional
derivatives (Fmoc-Bcmg(OtBu)2-OH). The nucleophilic addition to the nitroacetate
anion may be extended to a variety of electrophiles, including benzyl aldehyde and α,β, γ,δ-unsaturated nitroolefin. Described below is a suggested synthetic approach to the
ααAA analogue of lysine via nucleophilic addition of ethyl nitroacetate with α,β-, γ,δunsaturated nitroolefin (Figure 5.1). Based on previously reported procedure of
mono-alkylation of nitroacetate with nitrodiene, 5.10 the dialkylation will be
carried out using DIEA/TBAB in DMF. It will be interesting to test if the prevalent

O2N

CO2Et

O2N

DIEA, TBAB

CO2Et

O 2N

1. [H]

CO2Et

2. Boc2O, TEA

H H H
H2C C C C NO2

O2N

NO2

BocHN

NHBoc

1. H2/Ni

FmocHN

CO2H

H2N

TMS-Cl, DIEA

2. OH-/EtOH

CO2H

Fmoc-Cl
BocHN

NHBoc

BocHN

NHBoc

Figure 5.1 Synthetic approach towards the ααAA analogue of lysine.
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product of the dialkylation is the derivative from addition at the δ position of the
nitrodiene. Michael type addition at the β position of the diene may also occur
and result in mixed dialkylated products. Next, the primary nitro groups and
double bonds on the side chains of the derivative will be hydrogenated, then
protected by t-butyloxycarbonyl group. Subsequent hydrogenation of the tertiary
aliphatic nitro group with Raney Nickel and hydrolysis of the ethyl acetate will give
the free amino acid which should allow for the preparation of orthogonally protected
ααAA analogue of lysine.
Chapter 4 of this dissertation addresses the synthesis of novel β-strand mimics
and its application to the development of potential inhibitors of amyloid fibril.
Incorporation of sterically hindered ααAAs such Dbzg into alternating peptide sequence
position imposed specific constraints on peptide backbone and thus induced extended
conformation. Coupling with sterically demanding ααAAs was difficult, mainly due to
the proximity of N- and C- terminus to the congested α-carbon in ααAA. It was
observed that coupling at N-terminus of ααAA was more difficult than at the Cterminus. In this study, the acylation of N-terminus of Dbzg or Dibg using in situ
reagents such as PyAOP, HOAt, or HATU only gave low coupling yields after
prolonged reaction time. To overcome the difficulties in acylation of sterically hindered
ααAAs, pre-formed amino acid symmetrical anhydrides were employed as a means to
extend the peptide chain. It was observed that symmetrical anhydrides were efficient
reagents for acylation of N-terminus of highly hindered ααAAs in non-polar solvents
with the absence of base. Based on this coupling method, a potential inhibitor (AMY-1)
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of amyloid fibril was assembled. This blocker peptide was designed based on the
hydrophobic core Aβ16-20, where ααAAs analogues of natural amino acids in the core
were placed at alternating sequence positions. This parallel blocker peptide has shown
promising inhibitory activity against Aβ10-35 aggregation in phosphate buffer solution.
The aggregation of Αβ10−35 has been dramatically reduced in the presence of AMY-1 at
either room temperature or 37 ºC. Currently, the aggregation study using dynamic light
scattering (DLS) and fluorescence spectroscopy is in progress, and the results should
further reveal the inhibitory activity as well as biophysical property of this blocker
peptide. Potential future study includes preparation of the parallel blocker peptide
AMY-2: H-Lys-Dibg-Val-Dbzg-Phe-Dpg-CONH2
AMY-3: H-Dpg-Phe-Dbzg-Val-Dibg-(Lys)7-CONH2
AMY-4: H-Dpg-Phe-Dbzg-Val-Dibg-Lys-CONH2
without oligolysine at the C-terminus (AMY-2), and the preparation of anti-parallel
blocker peptides with/without oligolysine (AMY-3, AMY-4). It has been reported that
incorporation of oligolysine at the C-terminus of certain recognition sequence of
amyloid hydrophobic core can prevent elongation of the amyloid β-structures.5.12 The
inhibitory activities of AMY-2 will be studied and compared to AMY-1 to probe the βsheet blocking property of the hydrophobic core in the blocker peptide. The anti-parallel
blocker peptides AMY-3 and AMY-4 will be studied for their binding and inhibitory
activities against Aβ. The conformational behavior and biological activities of the
parallel and anti-parallel blocker peptides will be compared, upon which potential
inhibitors with optimized properties may be developed.
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APPENDIX A
NMR SPECTRA OF COMPOUNDS 3.1, 3.4-3.7

1

H NMR of 3.4a in DMSO-d6

129

13

C NMR of 3.4a in CDCl3

130

1

H NMR of 3.4b in DMSO-d6

131

13

C NMR of 3.4b in DMSO-d6

132

1

H NMR of 3.4c in DMSO-d6

133

13

C NMR of 3.4c in DMSO-d6

134

1

H NMR of 3.4d in CDCl3

135

13

C NMR of 3.4d in CDCl3

136

1

H NMR of 3.4e in CDCl3

137

13

C NMR of 3.4e in CDCl3

138

1

H NMR of 3.4f in CDCl3

139

13

C NMR of 3.4f in CDCl3

140

1

H NMR of 3.4g in CDCl3

141

13

C NMR of 3.4g in DMSO-d6

142

1

H NMR of 3.4h in DMSO-d6

143

13

C NMR of 3.4h in DMSO-d6

144

1

H NMR of 3.4i in DMSO-d6

145

13

C NMR of 3.4i in DMSO-d6

146

1

H NMR of 3.5a in DMSO-d6

147

13

C NMR of 3.5a in DMSO-d6

148

1

H NMR of 3.5e in CDCl3

149

13

C NMR of 3.5e in CDCl3

150

1

H NMR of 3.5h in DMSO-d6

151

13

C NMR of 3.5h in DMSO-d6

152

1

H NMR of 3.6h in DMSO-d6

153

13

C NMR of 3.6h in DMSO-d6

154

1

H NMR of 3.1a in MeOH-d4

155

1

H NMR of 3.1e in MeOH-d4

156

13

C NMR of 3.1e in MeOH-d4

157

1

H NMR of 3.7a in CDCl3

158

13

C NMR of 3.7a in CDCl3

159

1

H NMR of 3.7e in CDCl3

160

13

C NMR of 3.7e in CDCl3

161

APPENDIX B
LETTERS OF PERMISSION

162

163

164

VITA
Yanwen Fu graduated from Wuxi Institute of Light Industry, JiangSu, China, in
June 1989, where received his bachelor of science degree in chemical engineering. In
1994, he attended the University of Louisiana at Monroe and began his graduate studies
under the direction of Dr. Mark Arant. When he earned his master’s degree in organic
chemistry, he was the recipient of “The 1995-96 American Institute of Chemist Award
for Outstanding M.S. Graduate”. In 1997 he began his graduate studies at Louisiana
State University under the guidance of Dr. Robert P. Hammer. He will receive the
degree of Doctor of Philosophy in December of 2002.

165

